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Abstract: The tissue turnover of unperturbed adult lung is remarkably slow. However, after injury or
insult, a specialised group of facultative lung progenitors become activated to replenish damaged
tissue through a reparative process called regeneration. Disruption in this process results in healing by
fibrosis causing aberrant lung remodelling and organ dysfunction. Post-insult failure of regeneration
leads to various incurable lung diseases including chronic obstructive pulmonary disease (COPD) and
idiopathic pulmonary fibrosis. Therefore, identification of true endogenous lung progenitors/stem
cells, and their regenerative pathway are crucial for next-generation therapeutic development. Recent
studies provide exciting and novel insights into postnatal lung development and post-injury lung
regeneration by native lung progenitors. Furthermore, exogenous application of bone marrow stem
cells, embryonic stem cells and inducible pluripotent stem cells (iPSC) show evidences of their
regenerative capacity in the repair of injured and diseased lungs. With the advent of modern tissue
engineering techniques, whole lung regeneration in the lab using de-cellularised tissue scaffold
and stem cells is now becoming reality. In this review, we will highlight the advancement of our
understanding in lung regeneration and development of stem cell mediated therapeutic strategies in
combating incurable lung diseases.
Keywords: lung development; lung regeneration; lung stem cells; stem cell-mediated therapeutics;
signalling pathways in lung repair; lung tissue engineering
1. Introduction
The tissue turnover of unperturbed adult lung is remarkably slow. However, after injury or insult
a specialised group of facultative lung progenitors become activated to replenish damaged tissue
through a reparative process called regeneration. Interruption in this process results in healing by
fibrosis causing scarring, aberrant lung remodelling and organ dysfunction [1,2]. A highly specialised
group of endogenous lung stem/progenitor cells are believed to maintain lung homeostasis and
regeneration. In this review we will discuss our latest understanding of the identity of lung stem
cells, their activation and proliferation with subsequent differentiation to replenish or repair injured
lung tissues. This will include a discussion of lung development and the associated signalling that
governs this process. Evidence suggests that in some disease conditions, such as COPD, the embryonic
lung developmental process could be reactivated [3–5]. Furthermore, for de novo derivation of lung
progenitors from pluripotent embryonic stem cells (ESCs) and inducible pluripotent stem cells (iPSC)
in vitro, it is essential to understand the molecular pathways that regulate differentiation of adult lung
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cells from a common embryonic foregut endoderm origin. Exogenous stem cells, such as mesenchymal
stem cells (MSCs) and ESCs are involved in research designed to identify clinical applications in lung
disease and this will also be investigated.
2. Lung Development and Associated Signalling Pathways
Mammalian lung development is a complex but continuous process that starts at approximately
embryonic day 9 (E9.0) in mice, and at an undefined early time in human, and continues through
infancy [6]. The early embryonic and pseudoglandular stages elaborate the conducting airways,
and in later stage canalicular, saccular and alveolar development takes place through reduction of
mesenchyme and formation of pulmonary vasculature to form a thin air-blood barrier. A new-born
infant possesses approximately 50 million alveoli but will add another 250 million alveoli through
infancy increasing surface area from approximately 3 to 70 m2. In a completely developed lung there
are more than 40 different cell types, with different functions [7].
During embryonic weeks 3 to 7, the human lung originates as a ventral diverticulum arising
from the foregut endoderm, which bifurcates and gives rise laterally to the two primary bronchial
buds (Figure 1). The lung buds grow into surrounding splanchnic mesoderm and branch repeatedly,
giving rise to the future respiratory tree. This primitive lung bud is lined by epithelium derived from
foregut endoderm, which later differentiates into specialised cells that line both the conducting and
respiratory airways [7,8]. On the other hand, mesenchymal cells condensed around the primitive
airways differentiate into blood vessels, smooth muscle, cartilage, and other connective tissues of
the lung [9]. During embryonic weeks 7 to 16, an extensive branching morphogenesis takes place
through rapid proliferation of the primitive airways. This bronchial tree branching pattern does not
change after this stage and remains more or less unchanged throughout the adult life [10]. This is
the pseudoglandular stage. Here, the most peripheral structures including the terminal bronchioles,
respiratory bronchioles and alveolar ducts form. The cartilage begins to form around the larger airways
and smooth muscle forms around airways and major blood vessels. In this phase, the airways are
lined by columnar epithelium with few ciliated and goblet cells [10,11].
During the canalicular and saccular stages (embryonic weeks 16 to 35), the pulmonary acinar
units form which contain alveolar ducts, alveolar sacs and alveoli. A gradual decrease in mesenchymal
tissue results in close apposition of the pulmonary vasculature to the alveolar walls. At this time, type
I alveolar epithelial cell (AECI) and type II AEC (AECII) are differentiated from the cuboidal epithelial
cells in the most peripheral parts of the lung. Lamellar bodies associated with surfactant synthesis
begin to appear in the cytoplasm of AECII cells and AECI cells begin their flattening process and
attenuate to provide an air-blood interface [11]. This alveolar development continues after birth and is
completed through infancy [12].
During lung organogenesis, the proximodistal patterning, branching morphogenesis,
alveolarisation and cellular differentiation are strictly regulated by the surrounding mesenchyme
and a number of key growth factor-directed signalling pathways [13]. Cumulative data from
several recombination experiments reveal that mesenchyme is essential for initial lung budding
and subsequent branching of foregut endoderm, where the governing stimulation is carried out
by the qualitative and quantitative differential distribution of surrounding mesenchyme [14–17].
This reciprocal endoderm-mesoderm cross-talk is likely mediated by numerus soluble growth factors
and transcription factors originating from both epithelial and mesenchymal cells (Figure 1) [18–20].
Mouse embryonic lung organ culture experiments demonstrate that the quantity of mesenchyme
specifies epithelial cell fate during differentiation. That is, a small amount of mesenchyme is able to
direct cell differentiation toward a bronchiolar phenotype; whereas, an increased amount of the same
mesenchyme is able to induce the epithelial cells to differentiate toward an alveolar phenotype [21].
Furthermore, tissue recombination experiments show that distal lung mesenchyme can reprogram rat
tracheal epithelial cells to an AECII cell phenotype, and conversely, proximal mesenchyme can induce
distal lung epithelium towards a tracheal epithelial cell phenotype [22,23]. These findings highlight
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the significance of the epithelial-mesenchymal interaction in coordinating the precise temporospatial
pattern of lung development.Int. J. Mol. Sci. 2016, 17, 128 3 of 26 
 
 
Figure 1. Epithelial-mesenchymal cross-talk and governing signalling during early development and 
branching morphogenesis of lung. Factors are represented only at sites where the expression is most 
abundant. Fibroblast growth factor-10 (FGF-10) is highly expressed in the distal mesenchyme and acts 
as a chemotactic focus for the epithelium during lung budding. FGF-10 also regulates Sox9 expression 
in the distal epithelial progenitors and induces bone morphogenetic protein (BMP)-4 expression. Sox2 
expression in the proximal epithelium is under regulation of histone deacetylases 1/2 (HDAC1/2) 
signalling. FGF-10 expression in the mesenchyme is regulated by Wnt/β-catenin signalling (red 
arrow). A high concentration of BMP-4 signal also serves to locally inhibit endoderm proliferation, 
thereby inducing the lateral outgrowth of new airway branches. Sonic hedgehog (Shh) at the distal 
tips functions to downregulate FGF-10 expression in the mesenchyme, which limits local budding. 
Transforming growth factor-β (TGF-β) signalling also prevents local budding, by decreasing 
endodermal proliferation and by stimulating synthesis of matrix components at branch points. Solid 
arrows indicate sources from and influences on cells/molecules; dotted arrow indicates direction of 
patterning.  
At least 11 different epithelial cell types have been identified in the conducting and respiratory 
portions of the lung [24]. The basal, secretory, and ciliated cells are the major cell types constituting 
the pseudostratified epithelium of the proximal tracheobronchial area while AECI and AECII cells 
make up the alveolar epithelium [25]. The onset of cell differentiation is signalled by various gene 
products including surfactant protein (SP)-A, SP-B, SP-C, SP-D and club (Clara) cells secretory 
protein (CCSP) [26–29]. During early embryonic development, the undifferentiated epithelium co-
expresses several lineage markers including SP-A, CCSP and neuroendocrine cell markers. But later, 
during the pseudoglandular phase, this epithelium differentiates into different lineages and becomes 
restricted to proximal and distal airways [30]. Transcriptional analysis reveals that the surfactant 
proteins and CCSP genes share common mechanisms for gene regulation and expression in 
respiratory epithelial cells. Nkx2.1 (also known as thyroid transcription factor-1 (TTF-1)), a 
homeodomain protein, plays a pivotal role in several phases of lung development, including 
epithelial cell lineage determination [31–34]. Nkx2.1 binds and activates SP-A, SP-B, SP-C, and CCSP 
promoter elements as well as Nkx2.1 itself [35–39]. During development of the respiratory 
epithelium, Nkx2.1 appears to be the earliest marker, with onset of expression at the time of lung bud 
formation from the foregut endoderm [40]. Expression of Nkx2.1 is present throughout the foetal 
lung including respiratory epithelial cells of the trachea, bronchi, and developing respiratory tubules, 
but its expression is most robust in distal alveolar epithelium [24,40,41]. Null mutation of Nkx2.1 in 
mice exhibit tracheoesophageal fistulas and fail to form bronchiolar and alveolar structures [32–34]. 
Pulmonary-specific gene expression including SP-B, SP-C, and CCSP is extinguished within 
Figure 1. Epithelial-mesenchymal cross-talk and governing signalling during early development and
branching morphogenesis of lung. Factors are represented only at sites where the expression is most
abundant. Fibroblast growth factor-10 (FGF-10) is highly expressed in the distal mesenchyme and acts
as a chemotactic focus for the epithelium during lung budding. FGF-10 also regulates Sox9 expression
in the distal epithelial progenitors and induces bone morphogenetic protein (BMP)-4 expression. Sox2
expression in the proximal epithelium is under regulation of histone deacetylases 1/2 (HDAC1/2)
signalling. FGF-10 expression in the mesenchyme is regulated by Wnt/β-catenin signalling (red arrow).
A high concentration of BMP-4 signal also serves to locally inhibit endoderm proliferation, thereby
inducing the lateral outgrowth of new airway branches. Sonic hedgehog (Shh) at the distal tips functions
to downregulate FGF-10 expression in the mesenchyme, which limits local budding. Transforming
growth factor-β (TGF-β) signalling also prevents local budding, by decreasing endodermal proliferation
and by stimulating synthesis of matrix components at branch points. Solid arrows indicate sources
from and influences on cells/molecules; dotted arrow indicates direction of patterning.
At least 11 different epithelial cell types have been identified in the conducting and respiratory
portions of the lung [24]. The basal, secretory, and ciliated cells are the major cell types constituting
the pseudostratified epithelium of the proximal tracheobronchial area while AECI and AECII cells
make up the alveolar epithelium [25]. The onset of cell differentiation is signalled by various gene
products including surfactant protein (SP)-A, SP-B, SP-C, SP-D and club (Clara) cells secretory protein
(CCSP) [26–29]. During early embryonic development, the undifferentiated epithelium co-expresses
several lineage markers including SP-A, CCSP and neuroendocrine cell markers. But later, during the
pseudoglandular phase, this epithelium differentiates into different lineages and becomes restricted to
proximal and distal airways [30]. Transcriptional analysis reveals that the surfactant proteins and CCSP
genes share common mechanisms for gene regulation and expression in respiratory epithelial cells.
Nkx2.1 (also known as thyroid transcription factor-1 (TTF-1)), a homeodomain protein, plays a pivotal
role in several phases of lung development, including epithelial cell lineage determination [31–34].
Nkx2.1 binds and activates SP-A, SP-B, SP-C, and CCSP promoter elements as well as Nkx2.1
itself [35–39]. During development of the respiratory epithelium, Nkx2.1 appears to be the earliest
marker, with onset of expression at the time of lung bud formation from the foregut endoderm [40].
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Expression of Nkx2.1 is present throughout the foetal lung including respiratory epithelial cells of
the trachea, bronchi, and developing respiratory tubules, but its expression is most robust in distal
alveolar epithelium [24,40,41]. Null mutation of Nkx2.1 in mice exhibit tracheoesophageal fistulas and
fail to form bronchiolar and alveolar structures [32–34]. Pulmonary-specific gene expression including
SP-B, SP-C, and CCSP is extinguished within transgenic lungs, which do, however, contain ciliated
and mucus-secreting cells [34]. Thus, Nkx2.1 is recognised as a “master gene” in maintaining the
lung morphogenesis as well as cytodifferentiation of certain epithelial cell lineages [24]. However,
targeted gene mutation studies confer that while Nkx2.1 is not required for initial specification of lung
primordia it is essential for pulmonary development and cell differentiation [33,42].
The precise regulatory function of Nkx2.1 in pulmonary cytodifferentiation is not well understood;
however, study reveals that Nkx2.1 has multiple binding sites for both ubiquitous and specific
transcription factors, including those of the hepatocyte nuclear factor (HNF) and GATA zinc
finger families [43–45]. GATA and HNF play crucial role for the development of the foregut
endoderm [46–48]. Multiple studies have identified HNF-3 binding sites in the SP-A, SP-B, and
CCSP promoter regions [35,49,50]. The HNF-3β null mutation results in an early embryonic lethal
phenotype with primitive foregut deformities, resulting in agenesis of lung and other foregut
derivatives [51]. While Nkx2.1, GATA and HNF play crucial role in cytodifferentiation and specification
of cell fate, the Homeobox (Hox) genes regulate the patterning of the lung during embryonic
development. Hox genes act as transcription factors and are consistently expressed throughout
the lung during development and maintain proximal-distal orientation of the lung as well as branching
morphogenesis [52–54]. Hoxb-3 and Hoxb-4 genes are expressed both in the proximal and distal
mesenchyme of the entire developing lung; whereas, Hoxb-2 and Hoxb-5 are restricted within
the mesenchyme of distal lung buds (Figure 1) [52]. Hoxb-3 transactivates the Nkx2.1 promoter,
which suggests that Hoxb-3 could regulate proximal-distal lung patterning in an Nkx2.1 depended
manner [24,31]. Mouse embryonic lung culture experimentation has demonstrated that retinoic acid
induces Hoxa-5, Hoxb-5 and Hoxb-6 gene expression; whereas, Hoxb-5 is negatively regulated by
epidermal growth factor (EGF) and transforming growth factor-β (TGF-β) [55,56]. Retinoic acid has
been demonstrated to facilitate the growth of proximal airways and gene expression at the expense
of distal structures in a dose-dependent manner; therefore, it is probable that Hox genes mediate the
retinoic acid-induced alteration in lung patterning [57,58].
Bone morphogenetic protein (BMP)-4, a member of the TGF-β family proteins, is also implicated
in the control of the proximal-distal patterning of the lung and in branching morphogenesis [58,59].
BMP-4 gene expression is restricted to the tips of distal buds and to the adjacent mesenchyme, which
locally inhibits endoderm proliferation and forces the outgrowth of lateral branches (Figure 1) [58].
Moreover, inhibition of BMP signalling results in complete proximalization of the respiratory
epithelium, including ciliated cells in the most distal portions of lungs. Therefore, it is hypothesised
that BMP proteins provide a concentration gradient to regulate proximal versus distal lung endoderm
differentiation [59]. Endodermal cells located at the periphery of the lung, which are exposed to high
levels of BMP-4, maintain a distal identity while cells below a certain threshold of the BMP-4 signal
initiate a proximal differentiation program [24].
The Sox2 and Sox9 transcription factors mark lung bud endoderm as proximal and distal epithelial
progenitors respectively (Figure 1). Sox2 regulates the differentiation of proximal progenitors into
secretory and ciliated epithelium; whereas, Sox9 directs distal progenitors into alveolar epithelial
cells [60–65]. During early lung development, fibroblast growth factor-10 (FGF-10), which is highly
expressed in the distal mesenchyme and is regulated by Wnt signalling (Figure 1), acts on the distal lung
epithelial progenitors to maintain them and prevent them from differentiating into proximal airway
epithelial cells by inducing Sox9 and repressing Sox2 expression [66–70]. When the lung epithelium
extends into the mesenchyme, more proximally located cells become less exposed to distally sourced
FGF-10 and gradually start to differentiate [20,69–72]. In contrast, studies show that suppression of
FGF-10 around the developing airway, as well as during late gestation and postnatal development,
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facilitates proper maturation of the lung epithelium [73–76]. Furthermore, ectopic overexpression of
FGF-10 at later stages of lung development blocks the alveolar differentiation program via induction
of Sox9 expression [66,72,77]. Therefore, FGF-10 is thought to maintain distal epithelial progenitor
population helping branching morphogenesis during early lung development in a Sox9 dependent
manner [78].
While Sox9+ progenitors are largely under regulation of FGF-10, the Sox2+ progenitors in the
lung endoderm are regulated by histone deacetylases 1 (HDAC1) and HDAC2 (Figure 1). HDAC1/2
deficiency leads to a loss of Sox2 expression resulting in suppression of proximal airway development.
This is mediated in part by de-repression of BMP-4, which is direct transcriptional target of HDAC1/2.
In contrast to development, postnatal loss of HDAC1/2 in airway epithelium does not affect the
expression of Sox2 or BMP-4 [79].
Despite high-sequence homology and affinity for the same cognate receptor, FGF-7 and FGF-10
exert distinct effects on the developing lung. FGF-7 predominantly influences airway branching by
promoting epithelial cell proliferation and expansion [18,80,81]. FGF-7 acts as differentiation factor in
developing lung. Lung organotypic culture experiments show that in absence of any mesenchyme
or serum, exogenous application of FGF-7 can induce AECII-like epithelial cell differentiation [81,82].
During postnatal life, alveolarisation is regulated by cooperative interaction of various FGFs with
FGFR-3 and FGFR-4 receptors [83]. Double mutation of these receptors results in postnatal pulmonary
lethality where alveolarisation is severely disrupted leading to an emphysematous phenotype.
This transgenic mouse phenotype also exhibits an abnormal elastin synthesis causing a lethal form of
parenchymal defect [83]. Furthermore, inactivation of the epidermal growth factor (EGF) receptors
affects AECII cell maturity, with decreased expression of the SP-C protein. In contrast, exogenous EGF
administration accelerates alveolar type-II cell differentiation in foetal lungs [84].
3. Endogenous Stem Cell Population of the Respiratory System
Endogenous adult lung stem and progenitor cells are regenerative cell populations important
for epithelial cell homeostasis and injury repair. In multiple adult organs, tissue-specific stem cells
have been identified as multipotent cells with the capacity for long-term self-renewal and the ability
to differentiate into other cell lineages. Tissue-specific stem cells are typically quiescent in normal
conditions and proliferate during injury repair [85–87]. The unperturbed adult lung is a remarkably
quiescent. Therefore, the detection of proliferative postnatal stem or progenitor cells that actively
take part in repair and regeneration has been challenging. Numerous studies attempting to identify
adult stem or progenitor candidates in the lung have used injury and disease models, primarily in
rodents. To date, studies of human and animal lung morphology have identified subsets of lung
epithelial cells with self-renewal and differentiation capacity, including basal cells (BC), secretory club
cells (formerly known as Clara cells) of the proximal and distal airways, and AECII cells of the alveoli
(Figure 2) [6]. All of these cells have the capacity to enter the cell cycle in response to lung injury [88–95].
More recently, advanced lineage tracing techniques have suggested that most types of lung epithelial
cells, except for ciliated cells, can proliferate and expand after injury to promote repair [96–100].
Identifying these stem/progenitor cell populations and understanding their healing mechanism is
important to harness the endogenous abilities of the lung to regenerate from a therapeutic perspective.
3.1. Trachea and Proximal Airways Stem Cells
The trachea and the principal bronchi (proximal airways) of both humans and mice are lined
with a pseudostratified epithelium composed of basal and luminal cells. Luminal airway cells include
secretory club cells, ciliated cells and neuroendocrine cells. In the humans and other mammals, the
airway epithelium also contains SPDEF and MUC5AC expressing goblet cells. In this region, secretory
club cells are marked by expression of secretoglobin family 1a member 1 (Scgb1a1+) [6]. The basal
cells, on the other hand, are believed to be the most important stem cells of upper airways, marked
by the expression of basal cell-restricted transcription factor p63, keratin (Krt)-5 (Krt5), Krt14, nerve
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growth factor receptor (NFGR) and cell-surface marker Pdpn (Figure 2A) [101–103]. This basal cell
population, both in mice and human, have extensive proliferative potential, self-renewal capacity and
ability to differentiate into secretory club and ciliated cells [102,104]. The 3D “tracheosphere” culture of
FACS-sorted pure population of Krt5+p63+NGFR+ basal cells shows clonal expansion of differentiated
cells which are positive for both ciliated and secretory club (Clara) cells [102,103].Int. J. Mol. Sci. 2016, 17, 128 6 of 26 
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differentiation. HDAC1 and HDAC2 are essential for secretory epithelial regeneration; (B) The 
bronchiolar lining epithelium of rodents lacks basal cells but contains variant club cells, secretory cells 
and ciliated cells; (C) Progenitor cell populations and their differentiated progeny in the lung 
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can generate AECI cells during homeostasis and after injury. Generation of alveolar epithelium by 
other cells, such as BASCs has yet to be supported by lineage tracing. The AECII to AECI 
differentiation signalling is not clear (marked by “?”), but AECII self-renewal and proliferation occurs 
via EGFR/KRAS signalling. Curved arrows indicate differentiation and line arrows indicate molecular 
or physical stimulus. 
An H1N1 influenza virus-induced mouse lung injury model recently demonstrated that 
following a sub-lethal viral infection p63+ basal cells in the bronchiolar epithelium underwent rapid 
proliferation and migration to damaged alveolar regions. Then, these migrated cells assemble into 
discrete, Krt5+ pods and express typical alveoli-associated markers. This study suggests that this 
p63+Krt5+ cell population plays a role as an intermediate in the reconstitution of the alveolar-capillary 
network eradicated by viral infection [105]. On the other hand, lineage-tracing studies in mice show 
that in an injury condition Scgb1a1+ secretory club cells can give birth to goblet cells, but goblets 
cannot be derived from ciliated cells [106]. Therefore, these basal and club cell population are 
considered as major stem/progenitor cells in the upper airways. The molecular mechanisms for basal 
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ciliat d cell differentiation. HDAC1 and HDAC2 are essential for secretory epithelial regeneration;
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occurs via EGFR/KRAS signalling. Curved arrows indicate differentiation and line arrows indicate
molecular or physical stimulus.
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An H1N1 influenza virus-induced mouse lung injury model recently demonstrated that following
a sub-lethal viral infection p63+ basal cells in the bronchiolar epithelium underwent rapid proliferation
and migration to damaged alveolar regions. Then, these migrated cells assemble into discrete, Krt5+
pods and express typical alveoli-associated markers. This study suggests that this p63+Krt5+ cell
population plays a role as an intermediate in the reconstitution of the alveolar-capillary network
eradicated by viral infection [105]. On the other hand, lineage-tracing studies in mice show that in
an injury condition Scgb1a1+ secretory club cells can give birth to goblet cells, but goblets cannot be
derived from ciliated cells [106]. Therefore, these basal and club cell population are considered as major
stem/progenitor cells in the upper airways. The molecular mechanisms for basal cell self-renewal and
differentiation are poorly understood. However, mouse tracheobronchial epithelium shows that Notch
signalling is greatly enhanced during repair and is required for activation in basal cells promoting their
luminal differentiation, primarily toward secretory lineages (Figure 2A). Signalling is also conserved
in basal cells of the human airway [107].
3.2. Distal Airway Stem Cells
The distal bronchiolar region of mouse lungs are lined with a single-layered epithelium consisting
of secretory club cells (Scgb1a1+ and Scgb3a2+), ciliated cells (Foxj1+ and Tubb4+) and neuroendocrine
(NE) epithelial cells (CGRP+) (Figure 2B). In human, an additional population of Krt5+p63+ basal
cells are also present in the bronchiolar lining of the airways, but their presence has not been well
documented in the rodent lung [108]. Neuroendocrine cells are clustered within the epithelium
as neuroendocrine bodies (NEBs) and are marked by expression of calcitonin gene-related peptide
(CGRP). Lineage tracing studies show that CGRP+ NE cells are capable of self-renew in uninjured
adult lung and can differentiate into secretory club and ciliated cells after naphthalene injury [109].
The unperturbed bronchiolar epithelium is remarkably quiescent. However, depletion of
bronchiolar epithelium by naphthalene-induced injury spares a subset of secretory club cells that
express Scgb1a1 but not cytochrome p450. These Scgb1a1+p450´ club cells, which survive from
naphthalene toxicity, are designated as facultative progenitors; and are capable of expanding
rapidly to regenerate the damaged airways by differentiating into new secretory club and ciliated
cell populations (Figure 2B) [108,110]. Moreover, Scgb1a1+p450´ club cell populations also can
self-renew and differentiate into ciliated epithelium during normal homeostatic turnover [111].
This particular subset of naphthalene resistant club cells is often called “variant club cells”. Interestingly,
these variant club cells are mostly localised surrounding NEBs and at the bronchoalveolar duct
junctions (BADJs) [110,112]. Activity of Notch signalling in the NEB microenvironment has recently
been identified [113,114]. Parabronchial smooth muscle cells, which line most of the proximal airways,
were proposed to help make up a niche capable of activating variant club cells. It has been shown that
naphthalene injury stimulates FGF-10 secretion by the parabronchial smooth muscle, which appears to
be necessary for regeneration of variant club cells [115].
The degree of injury has differential effects in its modulation of secretory club cell mediated airway
regeneration. For instance, mild injury initiates proliferation and expansion of randomly distributed
club cells, which in turn differentiate into ciliated epithelium and thus promote repair. On the other
hand, severe naphthalene injury results in activation of variant club cells located around NEBs and
within the BADJ which then regenerate the injured tissues [116]. A growing body of literature supports
the notion that region-specific variant club cells of the NEB and BADJ niches preferentially contribute
to bronchiolar repair and regeneration after significant depletion of secretory cells, most likely via
Notch and FGF-10 regulation [6].
3.3. Stem Cells of the Alveolar Region
Pulmonary gas exchange occurs in alveolar sacs which are lined by squamous type AECI and
cuboidal AECII cells. Squamous AECI cells are terminally differentiated cells that line approximately
95% of the alveolar surface through which gas exchange takes place; whereas, AECII cells secret
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surfactant proteins that prevent alveolar collapse [117]. Classically, AECII cells are categorised as the
progenitors for AECI cells which replenish alveolar lining during normal tissue turnover and during
repair after injury (Figure 2C) [118]. Significant numbers of in vivo studies have demonstrated that
postnatal injury to alveoli initiates AECII cell proliferation and differentiation into AECI cells in the
attempt of alveolar repair [93,94,119–123]. Recent genetic lineage-tracing experiments, combined with
in vitro experiments, showed that SP-C positive AECII cells self-renew and differentiate into type I
AEC progeny over about a year in normal conditions, however, if many AECII cells are specifically
ablated, the individual survivor AECIIs undergo rapid clonal expansion and daughter cell dispersal.
In addition, when Individual lineage-labelled AECIIs are placed into 3D culture, those cells give
rise to self-renewing “alveolospheres”, containing cells which express both AECII and AECI specific
markers [124].
Lineage tracing and clonal analysis have demonstrated that during development, AECI and AECII
cells arise directly from a bipotent progenitor cell; whereas, after birth new AECI cells derive from
a rare subtype of, self-renewing, long-lived, mature AECII cell that produces slowly expanding clonal
foci of alveolar renewal. This stem-cell like AECII function is broadly activated by hyperoxic AECI
injury. Furthermore, purified EGFR ligands, such as TGF-α, heparin-binding EGF, and NRG1 stimulate
AECII proliferation in vitro. However, none of these EGFR ligands can induce AECII differentiation
into AECI cells. On the other hand, oncogenic KRAS has shown to stimulate multifocal clonal AECII
cell expansion in vivo [125]. Thus, it has been postulated that alveolar injury induces a signalling
pathway transduced by EGFR-KRAS that controls AECII self-renewal, whereas a different signal
(as yet unknown) controls AECII differentiation into AECI cell type (Figure 2C) [125].
In the mouse, another population of cells which co-express Scgb1a1 and SP-C markers are found
at the BADJ area designated as bronchioalveolar stem cells (BASCs) (Figure 2C). These Scgb1a1+Sp-C+
BASCs can expand in vivo after bleomycin-induced lung injury, and the isolated cells can be
clonally expanded in vitro, where they show multipotent differentiation into bronchiolar and
alveolar lineages [126]. Lineage-tracing studies demonstrate that during development or after
hyperoxic alveolar injury, the BASCs do not contribute in alveolar reconstitution [71]. In contrast,
bleomycin-induced lung injury model shows that the BASCs are capable of generating AECIIs,
although their contribution is limited, and they do not seem to expand substantially [127,128].
Furthermore, co-expression of Scgb1a1 and SP-C is not unique to BASCs, occasionally some AECIIs
found throughout mouse alveolar regions also co-express both Scgb1a1 and SP-C [127]. As Scgb1a1
lineage tracing does not entirely distinguish airway BASCs from rare AECII cells, further confirmation
is required before defining BASCs as alveolar stem cells [6].
3.4. Lung Mesenchymal Stem Cells
Mesenchymal stem cells (MSCs) are present in the stromal tissue of many organs, including bone
marrow, adipose tissue, muscle, periosteum, dermis, and lung [129]. A multitude of studies have
confirmed the presence of MSCs in the lungs of mice [130–134], humans [135–137], and sheep [138,139].
Lung-derived MSCs share some common features with conventional bone marrow-derived MSCs
and fulfil the International Society of Cellular Therapy criteria for MSCs, including marker profile
and differentiation capacity [140]. Lung MSCs are also clonogenic when grown on Matrigel with
bFGF or hepatocyte growth factor [141,142]. However, the function of these lung MSCs is not
completely understood.
Lung MSCs localised at the distal tip of the branching airway epithelium secrete FGF-10, a critical
component of the signalling network that regulates BMP, Wnt, and sonic hedgehog (Shh) pathways
necessary for cytodifferentiation in the developing lung [143]. Lung MSCs also support the proliferation
and differentiation of airway epithelial stem cells in co-culture [144]. Recently, Hoffman and colleagues
showed that intravenous administration of lung MSCs alleviates elastase-induced emphysema and
increases survival through a paracrine-mediated anti-inflammatory mechanism [145].
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4. Signalling Pathways Involved in Postnatal Lung Injury Repair and Regeneration
To understand the molecular mechanisms that regulate the activation, expansion, and
differentiation of stem and progenitor cells in response to injury and repair is crucial to aid development
of targeted therapeutic strategies to combat lung diseases. The surrounding mesenchyme also plays
critical role in promoting lung stem cells during injury repair [146]. Unilateral pneumonectomy
(PNX) demonstrated that resection of a single lobe, leaving other lobes, intact, resulted in regrowth of
alveoli within the remaining lungs [147–149]. This “neoalveolarisation” occurs through activation and
proliferation of bronchiolar cells, AECII cells, endothelial cells and PDGFRα+ stromal cells [150–155].
The post-PNX progenitor cell activation and alveolar regeneration is believed to be regulated by elastin
content, and EGF/FGF mediated signalling pathways [156,157]. Other signalling pathways, including
Wnt and Notch, are known to play important roles in stem cell self-renewal and differentiation and to
play key roles in lung repair and regeneration.
4.1. Wnt Signalling
Wnt signalling is an essential regulator of early lung endoderm specification and development
and has been implicated in regulating regenerative responses [146]. During postnatal lung
repair and regeneration canonical Wnt signalling is activated in the epithelium of various lung
compartments [158–162]. Naphthalene-induced selective depletion of secretory club cells of airway
epithelium activates Wnt signalling. This activation of Wnt signalling through loss of the transcription
factor GATA6 leads to expansion of the BASCs population after naphthalene injury [163]. However,
canonical Wnt signalling may not be essential for lung regeneration as postnatal deletion of β-catenin
does not obliterate secretory cell proliferation [163]. Moreover, loss of β-catenin in postnatal alveolar
epithelium leads to increased fibrosis and AEC death [164]. In addition, blocking of Wnt signalling by
pharmacologically active molecules can reduce bleomycin-induced lung fibrosis [165]. Furthermore,
increased activation of Wnt signalling has been associated with idiopathic pulmonary fibrosis (IPF)
lesions [166]. Therefore, precaution should be taken with the manipulation of Wnt signalling in the
activation of lung progenitors to promote lung regeneration. Excessive activation of Wnt signalling
may lead to fibrosis and other deleterious effects [6].
4.2. Notch Signalling
Notch signalling plays an important role in airway epithelial regeneration. During lung
development, Notch signalling is essential for differentiation of the secretory epithelium from proximal
lung endoderm [167,168]. In postnatal lung injury, Notch signalling is essential for differentiation of
basal cells into secretory cells [107]. Increased Notch activation can expand the secretory lineage at the
expense of the ciliated lineage [107,169]. In addition, reactive oxygen species (ROS) activate Notch
signalling via Nrf2 activation. The ROS-Notch pathway is important for BC self-renewal through
regulation of cell proliferation, which may be critical for maintaining the BC population in the upper
airways of rodent and human lungs [170]. This unique ability of Notch to promote a specific secretory
cell lineage differentiation may offer a potential therapeutic target to activate lung resident stem cells
towards promotion of airway epithelial regeneration after acute lung injury [6].
4.3. Histone Deacetylases (HDACs) Signalling
Histone deacetylases (HDACs) are enzymes that eliminate acetyl groups from histones and
modulate gene function. Genetic deletion of HDAC1 and HDAC2 in postnatal secretory club cells in
mice led to the induction of tumour suppressor genes Rb1, p21, and p16 after naphthalene injury, which
resulted in inhibition of club cell proliferation and permanently impaired epithelial regeneration [79].
This finding indicates that HDAC1 and HDAC2 may play important role in airway epithelial
regeneration after injury in postnatal lung. HDAC may also play important role in the regulation of
AECII function during development and regeneration in a Hop-dependent manner. Hop is an unusual
Int. J. Mol. Sci. 2016, 17, 128 10 of 27
homeodomain protein expressed in airway epithelium coincident with HDAC2, acting downstream of
Nkx2.1 and GATA6 signalling pathways to negatively regulate surfactant protein expression by the
AECII cells. Loss of Hop expression in vivo results in defective AECII cell development with increased
surfactant production and disrupted alveolar formation. This Hop-mediated regulation of alveolar
maturation is found to be HDAC-dependent [171]. Individuals with COPD have a significant decrease
in HDAC activity in their lung epithelia with an associated complete loss of HDAC2 expression [172].
In asthma, bronchial epithelium displays reduction of HDAC activity as well [173]. Taken together,
this suggests that HDACs have an important role in pulmonary epithelium homeostasis and repair.
Therefore, pharmacological interventions targeting HDACs to increase histone acetylation and gene
expression could have therapeutic benefits in promoting lung regeneration.
4.4. miRNAs and lncRNAs Regulation
Noncoding micro RNAs (miRNAs) and long noncoding RNAs (lncRNAs) play crucial roles in
epithelial branching and differentiation during lung development. Two miRNA clusters, miR17-92
and miR302-367 play important roles in lung epithelial proliferation and differentiation. Both of these
clusters are highly expressed during early lung development and then are significantly downregulated
by birth [174,175]. Overexpression of these miRNA clusters results in increased lung epithelial
proliferation at the expense of differentiation inhibition [174,176]. On the other hand, a recent study
identified hundreds of lncRNAs expressed in the developing and postnatal lung [177]. A subset of
these lncRNAs is located near to transcription factors Nkx2.1 and Foxf1. One of these lncRNAs, called
NANCI, has been found to regulate SP-C and Scgb1a1 expression. Therefore, modulation of noncoding
RNA candidates could be another way to activate and pulmonary regeneration process during disease
condition as therapeutics [146].
5. Effects of Matrix Components in Lung Regeneration
The focus of this review is primarily to discuss the cellular components and their participation in
lung regeneration; however extracellular matrix (ECM) also plays an important role. The ECM
components play key roles in lung development, injury repair, regeneration and disease
pathogenesis [178]. The major components of the lung ECM are collagen and elastin, interwoven with
fibronectin and proteoglycans, that provide plasticity of the lung parenchyma [179]. Other important
native lung ECM components are laminins, heparan sulfate proteoglycans, entactin, hyaluronate,
chondroitin sulfate, and glycosaminoglycans [180]. In the lung, collagen subtypes I and III provide
structural integrity, while collagen IV is predominantly a basement component [180,181]. Fibronectin
is important for the adherence of a variety of pulmonary cell types to the ECM, and regulates cellular
morphology, motility, and differentiation [182]. A wide range of matrix molecules mediate the fate of
epithelial cell differentiation. For instance, AECIIs maintain their phenotype on collagen and laminin-5
substrates, but differentiate towards AECIs when cultured on collagen or laminin-5 alone [183,184].
ECM also significantly impacts stem cell differentiation. It has been reported that laminin-332 and
Matrigel coatings led to increased SP-C expression by ESC-derived AECII cells [185]. For more
understanding in the effects of ECM in the stem cell niche, physical stimuli and ECM-growth factor
interaction in lung regeneration the following ECM-focused reviews are recommended [186,187].
6. Exogenous Stem Cell Interventions in Regenerative Therapies
6.1. Differentiation of ESCs and iPSCs into Pulmonary Epithelium
Pluripotent embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) offer
enormous potential for regeneration of injured tissue and repair of disease states. ESCs are isolated
from the inner cell mass of preimplantation blastocysts of an early mammalian embryo, and they
can be maintained indefinitely in an undifferentiated state with the ability to differentiate into cells
of all three embryonic germ layers [188]. On the other hand, iPSCs are classically generated by
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reprogramming fibroblasts by retroviral transduction of the transcription factors Klf4, Sox2, Oct4, and
c-Myc. Once generated, iPSCs show all features of pluripotent ESCs and are capable of differentiation
into cells of all three embryonic germ layers [189–191]. The possibility of patient-specific iPSCs
offers great hope for generating genetically matched patient-specific lung progenitor cells, with the
opportunity for patient specific regenerative cell therapy and drug screening as well as in vitro
modelling of human diseases [87].
ESCs, in in vitro culture can perform differentiation reminiscent of the early embryo; therefore,
efforts have been taken to direct differentiation of ESCs towards lung progenitors by applying
signalling transduction that occurs during lung development. Definitive endoderm progenitor cells of
the developing foregut give rise to the differentiated tissue of the thyroid, lung, liver, and pancreas.
The lung epithelia development progresses through a primordial progenitor stage defined by the
onset of Nkx2.1 expression and downregulation of Sox2 [34,40,63]. In the later stage of development,
Sox2 expression increases in the area of the future lung trachea, bronchus, and bronchioles where the
Nkx2.1-expressing progenitor cells of the embryonic lung giving rise to mature airway epithelium [63].
Sox9 and FoxP2 are expressed in the distal embryonic lung and mark a multipotent embryonic lung
progenitor population [192,193].
Initial attempts to generate functional lung epithelium from ESCs generated mixed cell
populations with the risk of teratoma formation after transplantation because of the remaining
undifferentiated pluripotent stem cells [194]. To overcome this risk, Green et al. [195] found that dual
inhibition of TGF-β and BMP signalling after specification of definitive endoderm (directed via Activin
treatment) from ESCs highly enriches anterior foregut endoderm for the next steps in differentiation.
Recently, definitive endoderm has been derived from mouse ESCs and converted first into foregut
endoderm, and then into Nkx2.1+ lung endoderm using precisely-timed TGF-β, BMP-4, FGF-2,
and Wnt signalling. Nkx2.1+ lung endoderm was then converted into multipotent embryonic lung
progenitor and airway progenitor cells with the formation of “tracheospheres” when subcutaneously
transplanted into nude mice [196]. Using the same differentiation technique, Mou et al [196] were able
to generate disease-specific lung progenitor cells from human Cystic Fibrosis iPSCs, and these lung
progenitors formed respiratory epithelium when subcutaneously engrafted into immunodeficient mice.
Similarly, Longmire et al. [197] purified and directed differentiation of ESCs following initial
inhibition of TGF-β and BMP signalling, and then via stimulation of BMP-4 and FGF-2 signalling
to form definitive endodermal precursors able to re-cellularise a 3D lung scaffold. An in vitro
directed differentiation protocol has also been developed for generating functional cystic fibrosis
transmembrane conductance regulator (CFTR)-expressing airway epithelia from human ESCs [198].
Carefully timed treatment by exogenous growth factors (FGF-7, FGF-10, FGF-18 and BMP-4) followed
by air-liquid interface culture stimulated the differentiation of hESCs into airway epithelial cells that
express functional CFTR [198]. Very recently, Huang and colleagues have derived lung progenitor
cells (with ~80% efficiency) from hESC/iPSCs, which were capable of differentiating into airway
and alveolar epithelial cells in vitro and in vivo [199]. Through refinement of the differentiation
protocol, they first derived definitive endoderm from hESC (and iPSC) by Activin/BMP-4/bFGF
treatment. This definitive endoderm was then sequentially exposed to the BMP inhibitor dorsomorphin,
TGF-β inhibitor SB431542 and endogenous Wnt blocker IWP2 for shorter period, followed by
a longer exposure to CHIR99021 (a small molecule that mimics Wnt signalling), FGF-10, KGF,
BMP-4 and retinoic acid for derivation of anterior foregut endoderm. These lung progenitors were
then differentiated into variety of pulmonary epithelial/progenitor cells including basal cells, club
(Clara) cells, goblet cells, ciliated cells, AECII and AECI in vivo in immunodeficient mice and in vitro
culture [199]. Tremendous efforts to better understand the details of ESCs- and iPSCs-directed
differentiation in the pulmonary field are ongoing, showing great progress and therapeutic promise.
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6.2. MSC-Mediated Regenerative Therapies
MSCs have been recently evaluated as a potential cell-based therapy for lung diseases. Preclinical
studies and clinical trials demonstrate that the application of MSC stimulates wound repair and
regeneration with efficient amelioration of a number of clinical conditions [200–203]. The precise
mechanism of MSC-mediated wound repair and regeneration is not clear; however, evidence suggests
that paracrine mechanisms are likely to be involved. One of the unique properties of MSCs is their
site-specific migration and engraftment to injured tissues and differentiation into specific cell types.
A variety of experimental animal models suggest active participation in wound repair and tissue
regeneration [201–203]. On the other hand, some studies demonstrate that MSC-secreted paracrine
factors play a vital role for wound repair, most likely through their anti-inflammatory, anti-apoptotic,
angiogenic and immunomodulatory properties [204–209]. Additional reports suggest that MSC
secretory products are capable of stimulating tissue-specific regional progenitor cells propagating tissue
regeneration [210,211]. Recent evidence suggests that in addition to releasing soluble anti-inflammatory
factors, the MSCs transfer microvesicles containing mitochondria, protein, and microRNAs to other
cells [212,213]. Paracrine-modulating factors secreted by MSCs appear to be responsible for injury
repair rather than MSC engraftment [213]. MSCs can be readily isolated from a variety of human
tissues including bone marrow, adipose tissue, placenta, Umbilical cord and peripheral blood [214].
MSC-based regenerative therapy has been studied in pre-clinical animal models of several incurable
and devastating lung diseases, with promising results are outlined below (reviewed in [214]).
Acute respiratory distress syndrome (ARDS) is a common and devastating clinical syndrome
of acute lung injury (ALI) caused by various direct and indirect insults including infection, trauma,
and major surgery. It can result in respiratory failure and ultimately death [215]. Several animal
model studies demonstrate compelling data on the beneficial effects of MSCs in resolving acute lung
injuries induced by endotoxin [216–219], hyperoxia [220], pneumonia [221] and systemic sepsis [206].
In a recent description, endotoxin-induced lung injury in explanted human lungs was ameliorated
with the infusion of MSCs [206]. The accumulation of this pre-clinical data offers considerable hope
that MSCs could be a potential candidate for the effective therapy of ARDS. Very recently, a Phase I
clinical trial has been completed to evaluate the safety of single dose intravenous administration of
allogenic bone marrow-derived MSCs in a cohort of nine moderate-to-severe ARDS patients. Single
dose MSCs administration was well tolerated without any intervention-associated adverse effect or
death [222]. Based on this result, a Phase II clinical trial has been started.
Evaluation of the lipopolysaccharide (LPS)-induced mouse ALI model demonstrates that
intravenous or intratracheal administration of MSCs significantly attenuated LPS-induced pulmonary
inflammation and alveolar injuries, improved alveolar fluid clearance, and reduced mortality [217].
This improvement of the pulmonary condition occurs in the absence of any significant engraftment of
MSCs in the lung, suggesting a paracrine role of MSCs in the alleviation of ALI via suppression of
pro-inflammatory cytokines tumour necrosis factor (TNF)-α and upregulation of anti-inflammatory
cytokine IL-10 [217]. In support of MSC-paracrine mediated anti-inflammatory effects, Ortiz and
colleagues demonstrates that MSCs and/or acellular conditioned media collected from cultured MSCs
attenuates acute pulmonary inflammation. This attenuation was via suppression of both IL-1α-dependent
T-lymphocyte proliferation and inhibition of TNF-α secretion by activated macrophages via
MSC-secreted IL-1 receptor antagonist in vitro and in the bleomycin-induced murine lung injury
model [207]. Furthermore, under inflammatory condition MSCs can be stimulated by pro-inflammatory
cytokines and endotoxins, such as TNF-α and LPS. Endotoxin-mediated MSC activation occurs
via toll-like receptor-4, resulting in increased production of cyclooxygenase-2 and increased
prostaglandin-E2 release. MSC-secreted prostaglandin-E2 leads increased macrophage IL-10 secretion
and thus can attenuate sepsis and sepsis-associated lung injury [206].
The therapeutic potential of MSCs has also been tested and shows promise in several chronic
lung conditions including chronic obstructive pulmonary disease (COPD), idiopathic pulmonary
fibrosis (IPF), bronchial asthma and pulmonary hypertension (PH). PH is a progressive disease
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with ongoing endothelial dysfunction and vascular remodelling. MSC administration has shown
therapeutic benefits in murine models of PH [213]. Moreover, genetically engineered MSCs that
overexpress endothelial nitric oxide synthase, prostacyclin, or heme oxygenase-1 had even greater
reversal effects on PH [223,224].
IPF is a progressive disease currently without any effective therapy [225–227]. MSC delivery to
the bleomycin injury IPF mouse model has shown low levels of MSC engraftment, but significant
improvement in lung injury and fibrosis [228–230]. In 2007, Ortiz and colleagues showed that MSCs
protects against bleomycin-induced lung injury and reduced fibrosis by blocking pro-inflammatory
cytokines such as TNF-α and IL-1 by MSC-associated IL-1 receptor antagonist [207]. The administration
of KGF-expressing MSCs in the bleomycin-induced mouse lung fibrosis model has shown reduced
fibrosis via suppression of collagen accumulation [228]. KGF has an established role in the repair of
alveolar epithelium through stimulation of AECII cell proliferation, migration and spreading [231–233].
Ongoing work continues to explore the possible benefits of treatment with MSCs for this lung disease
with high morbidity and mortality.
COPD is the fourth leading cause of death worldwide and has been projected to be the third
leading cause in 2020 [234]. No curative therapy is available for COPD at this time. COPD
is characterised by an ongoing cycle of repeated destruction and repair of bronchilo-alveolar
regions with subsequent tissue remodelling and sustained irreversible airway obstruction [235].
Systemic administration of bone marrow-derived MSCs was shown to ameliorate the emphysematous
changes in the irradiation and papain-induced experimental mouse COPD models [208]. In this
model, transplanted MSCs were localised to the emphysematous lung parenchyma and had
differentiated into AECII cells. This was accompanied by reduced alveolar epithelial cell apoptosis,
via Bcl-2 expression, and reduced enlargement of alveolar spaces [208]. Autologous intratracheal
transplantation of bone marrow MSCs significantly mitigated elastase-induced COPD in the rabbit
model [236]. The transplantation of bone marrow stem cells was associated with improved lung
function, an attenuation of inflammation, an inhibition of epithelial apoptosis, a decrease in matrix
metalloproteinase-2 expression, and the stimulation of alveolar and bronchiolar cell proliferation
where engraftment and differentiation of the transplanted stem was negligible [236].
A recent placebo-controlled, randomised, multi-centre clinical trial has examined treatment with
systemic MSCs for COPD and showed neither any adverse effects nor any differences in pulmonary
function tests or quality of life indicators [237]. This clinical trial showed important safety data, and it
provides a basis for further clinical trials to test the efficacy of MSC treatment in respiratory diseases.
Extensive work is ongoing to investigate the role of treatment with MSCs in lung diseases in both
mouse models of respiratory disease and human clinical trials.
7. Stem Cells in Lung Tissue Engineering
Research in the tissue engineering field is focused on exploration of 3-dimensional tissue culture
systems for use in development of functional lung tissue. The ultimate ambition of these studies
is to reduce donor-dependent lung transplantation [238,239]. The unique architecture of the lung
and its anatomical and physiological complexity presents a major challenge to tissue engineers.
Tissue engineered tracheas have been developed using MSCs isolated from various sources before
being cultured on biodegradable and biosynthetic scaffolds to generate tracheal cartilage for the
repair of congenital tracheal defects in both animal and human clinical trial models [240,241].
Very recently, a group of tissue engineers, stem cell researchers, and clinicians developed a functional
human airway by culturing MSC-derived chondrocytes on an acellular tracheal scaffold, which was
subsequently transplanted in a female patient who had suffered airway damage from tuberculosis [242].
A de-cellularised 7-cm long segment of human trachea was taken from a 51-year-old white female
donor and then the recipient’s bone marrow-derived MSCs were differentiated into chondrocytes
and airway epithelial cells were cultured in vitro. The MSC-derived chondrocytes were seeded on
the external surface of the de-cellularised trachea and airway epithelial cells seeded on the luminal
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surface, in an equal ratio, and cultured in an air-liquid interface rotating bioreactor for 96 h. After
in vitro preparation, the tracheal construct was transplanted to the left bronchus of the recipient,
which improved breathing difficulties without graft rejection [242]. This achievement encourages the
development of more complicated parts of the lung, such the alveoli and pulmonary vasculature, and
even the entire lung.
More recently, whole-lung tissue engineering has been attempted in animal models [243,244].
These approaches make use of whole-lung de-cellularisation strategies [245] followed by reseeding the
de-cellularised lung scaffold with primary airway epithelial cells, vascular endothelial cells [243,244],
whole lung cell suspension digests [243], MSCs [246,247], or differentiated ESCs or iPSCs [197,248,249].
After culture within a bioreactor, the organs were re-implanted into syngeneic recipients and
demonstrated efficient gas exchange [243,244]. The strategies for de-cellularising whole lungs
followed by re-cellularisation with lung progenitors/stem cells have been applied to pigs, nonhuman
primates [250], and human [251] lungs [252–254]. However, the complexity of human lung structure
and difficulties in reseeding cells into all desired compartments of lung have made this task challenging
and will take many years to establish and transplant a fully functional tissue-engineered whole-lung
for clinical use.
8. Conclusions
Lung disease is a major cause of morbidity and mortality worldwide. Despite being highly
quiescent, the lung’s ability to regenerate extensively after injury suggests that this regenerative
capability could be promoted and utilised in disease condition where loss of lung tissue occurs,
and the lung fails to regenerate. Endogenous stem cells are indispensable during normal tissue
turnover and repair or regeneration after injury to restore the function of an organ. This seems
to be true for the lung as well. However, understanding of the endogenous stem/progenitor cell
population involved and the underlying mechanisms that control the proper regeneration of lung tissue
remains broadly elusive. Although several animal injury models provide evidence of compartmental
stem/progenitor activation and proliferation, the underlying signalling pathway that initiates this
regenerative activity is largely unknown. Evidence suggests that, in many disease conditions, prenatal
lung developmental signalling is reactivated. Our understanding in mammalian lung development,
in particular the process of alveologenesis, is poorly understood. However, the recent advent of
organotypic ex vivo models, such as “tracheosphere” and “alveolosphere” culture offer novel platforms
for studying stem/progenitor dynamics and associated signalling pathways that could be involved in
lung regeneration. Furthermore, derivation of lung progenitors from ESCs and iPSCs for the repair
of lung after injury and disease condition opens another exciting avenue towards development of
regenerative therapeutics for lung disease. In this case, however, the pluripotent nature of ESCs or
iPSCs could present a potential risk of teratogenic effects, which needs to be rigorously addressed
before moving into human clinical trial. Much study, so far, has been done to evaluate MSC-mediated
cell therapy in various lung conditions, albeit mostly in animal models. In this case, it is important
to note that the bulk of studies suggest the infused MSCs exhibits reparative/healing effects mostly
through paracrine or immunomodulatory effects on recipient lung tissue, but not by engraftment.
Thus, it is imperative to view MSC therapy as cell-based immunomodulatory therapy rather than as
attempts to regenerate or reconstitute lung tissues [6]. Nonetheless, much effort has been taken to date
to understand the molecular mechanisms of lung development, disease dynamics and its regenerative
process. Much, of course, still remains to be determined. By combining the strength of basic studies
along with rational clinical approaches we can fully unravel the power and promise of next-generation
regenerative therapeutics in the field of lung disease in the coming years.
Acknowledgments: The authors wish to acknowledge the North Staffordshire Medical Institute and the
Guy Hilton Asthma Trust for their generous support.
Conflicts of Interest: The authors declare no conflict of interest.
Int. J. Mol. Sci. 2016, 17, 128 15 of 27
References
1. Beers, M.F.; Morrisey, E.E. The three R’s of lung health and disease: Repair, remodeling, and regeneration.
J. Clin. Investig. 2011, 121, 2065–2073. [CrossRef] [PubMed]
2. Wansleeben, C.; Barkauskas, C.E.; Rock, J.R.; Hogan, B.L. Stem cells of the adult lung: Their development and
role in homeostasis, regeneration, and disease. Wiley Interdiscip. Rev. Dev. Biol. 2013, 2, 131–148. [CrossRef]
[PubMed]
3. Pillai, S.G.; Ge, D.; Zhu, G.; Kong, X.; Shianna, K.V.; Need, A.C.; Feng, S.; Hersh, C.P.; Bakke, P.;
Gulsvik, A.; et al. ICGN Investigators. A genome-wide association study in chronic obstructive pulmonary
disease (COPD): Identification of two major susceptibility loci. PLoS Genet. 2009, 5, e1000421. [CrossRef]
[PubMed]
4. Wang, B.; Zhou, H.; Yang, J.; Xiao, J.; Liang, B.; Li, D.; Zhou, H.; Zeng, Q.; Fang, C.; Rao, Z.; et al. Association
of HHIP polymorphisms with COPD and COPD-related phenotypes in a Chinese Han population. Gene
2013, 531, 101–105. [CrossRef] [PubMed]
5. Wilk, J.B.; Chen, T.H.; Gottlieb, D.J.; Walter, R.E.; Nagle, M.W.; Brandler, B.J.; Myers, R.H.; Borecki, I.B.;
Silverman, E.K.; Weiss, S.T.; et al. A genome-wide association study of pulmonary function measures in the
Framingham heart study. PLoS Genet. 2009, 5, e1000429. [CrossRef] [PubMed]
6. Kotton, D.N.; Morrisey, E.E. Lung regeneration: Mechanisms, applications and emerging stem cell
populations. Nat. Med. 2014, 20, 822–832. [CrossRef] [PubMed]
7. Boyden, E.A. Development and growth of the airways. In Development of the Lung; Hodson, W.A., Ed.;
Marcel Dekker: New York, NY, USA, 1977; pp. 3–35.
8. Ten Have-Opbroek, A.A. Lung development in the mouse embryo. Exp. Lung Res. 1991, 17, 111–130.
[CrossRef] [PubMed]
9. Loosli, C.G.; Potter, E.L. Pre- and postnatal development of the respiratory portion of the human lung.
Am. Rev. Respir. Dis. 1959, 80, 5–23. [PubMed]
10. Bucher, U.; Reid, L.M. Development of intrasegmental bronchial tree: The pattern of branching and
development of cartilage at various stages of intra-uterine life. Thorax 1961, 16, 207–218. [CrossRef]
[PubMed]
11. Boyden, E.A. Development of human lung. In Brenneman’s Practice of Paediatrics; Kelley, V., Ed.;
Harper & Row: Hagerstown, MD, USA, 1980; pp. 1–17.
12. Langston, C.; Kida, K.; Reed, M.; Thurlbeck, W.M. Human lung growth in late gestation and in the neonate.
Am. Rev. Respir. Dis. 1984, 129, 607–613. [PubMed]
13. Warburton, D.; El-Hashash, A.; Carraro, G.; Tiozzo, C.; Sala, F.; Rogers, O.; de Langhe, S.; Kemp, P.J.;
Riccardi, D.; Torday, J.; et al. Lung organogenesis. Curr. Top. Dev. Biol. 2010, 90, 73–158. [PubMed]
14. Alescio, T.; Cassini, A. Induction in vitro of tracheal buds by pulmonary mesenchyme grafted on tracheal
epithelium. J. Exp. Zool. 1962, 150, 83–94. [CrossRef] [PubMed]
15. Spooner, B.S.; Wessells, N.K. Mammalian lung development: Interactions in primordium formation and
bronchial morphogenesis. J. Exp. Zool. 1970, 175, 445–454. [CrossRef] [PubMed]
16. Wessells, N.K. Mammalian lung development: Interactions in formation and morphogenesis of tracheal
buds. J. Exp. Zool. 1970, 175, 455–466. [CrossRef] [PubMed]
17. Hilfer, S.R.; Rayner, R.M.; Brown, J.W. Mesenchymal control of branching pattern in the fetal mouse lung.
Tissue Cell 1985, 17, 523–538. [CrossRef]
18. Nogawa, H.; Ito, T. Branching morphogenesis of embryonic mouse lung epithelium in mesenchyme-free
culture. Development 1995, 121, 1015–1022. [PubMed]
19. Deterding, R.R.; Shannon, J.M. Proliferation and differentiation of fetal rat pulmonary epithelium in the
absence of mesenchyme. J. Clin. Investig. 1995, 95, 2963–2972. [CrossRef] [PubMed]
20. Bellusci, S.; Grindley, J.; Emoto, H.; Itoh, N.; Hogan, B.L. Fibroblast growth factor 10 (FGF10) and branching
morphogenesis in the embryonic mouse lung. Development 1997, 124, 4867–4878. [PubMed]
21. Masters, J.R.W. Epithelial-mesenchymal interaction during lung development: The effect of mesenchymal
mass. Dev. Biol. 1976, 51, 98–108. [CrossRef]
22. Shannon, J.M. Induction of alveolar type II cell differentiation in fetal tracheal epithelium by grafted distal
lung mesenchyme. Dev. Biol. 1994, 166, 600–614. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2016, 17, 128 16 of 27
23. Shannon, J.M.; Nielson, L.D.; Gebb, S.A.; Randell, S.H. Mesenchyme specifies epithelial differentiation in
reciprocal recombinants of embryonic lung and trachea. Dev. Dyn. 1998, 212, 482–494. [CrossRef]
24. Deutsch, G.H.; Pinar, H. Prenatal lung development. In Chronic Obstructive Lung Diseases; Voelkel, N.F.,
MacNee, W., Eds.; BC Decker Inc.: London, UK, 2002; Chapter 2; pp. 1–14.
25. Ayers, M.M.; Jeffery, P.K. Proliferation and differentiation in mammalian airway epithelium. Eur. Respir. J.
1988, 1, 58–80. [PubMed]
26. Weaver, T.E.; Whitsett, J.A. Function and regulation of expression of pulmonary surfactant-associated
proteins. Biochem. J. 1991, 273, 249–264. [CrossRef] [PubMed]
27. Wert, S.; Glasser, S.; Korfhagen, T.; Whitsett, J.A. Transcriptional elements from the human SP-C gene
direct expression in the primordial respiratory epithelium of transgenic mice. Dev. Biol. 1993, 156, 426–443.
[CrossRef] [PubMed]
28. Singh, G.; Singh, J.; Katyal, S.L.; Brown, W.E.; Kramps, J.A.; Paradis, I.L.; Dauber, J.H.; Macpherson, T.A.;
Squeglia, N. Identification, cellular localization, isolation, and characterization of human Clara cell-specific
10 KD protein. J. Histochem. Cytochem. 1988, 36, 73–80. [CrossRef] [PubMed]
29. Hackett, B.P.; Shimizu, N.; Gitlin, J.D. Clara cell secretory protein gene expression in bronchiolar epithelium.
Am. J. Physiol. 1992, 262, L399–L404. [PubMed]
30. Wuenschell, C.W.; Sunday, M.E.; Singh, G.; Minoo, P.; Slavkin, H.C.; Warburton, D. Embryonic
mouse lung progenitor cells co-express immunohistochemical markers of diverse mature cell lineages.
J. Histochem. Cytochem. 1996, 44, 113–123. [CrossRef] [PubMed]
31. Guazzi, S.; Lonigro, R.; Pintonello, L.; Boncinelli, E.; di Lauro, R.; Mavilio, F. The thyroid transcription
factor-1 gene is a candidate target for regulation by Hox proteins. EMBO J. 1994, 13, 3339–3347. [PubMed]
32. Minoo, P.; Hamdan, H.; Bu, D.; Warburton, D.; Stepanik, P.; deLemos, R. TTF-1 regulates lung epithelial
morphogenesis. Dev. Biol. 1995, 172, 694–698. [CrossRef] [PubMed]
33. Kimura, S.; Yoshinobu, H.; Pineau, T.; Fernandez-Salguero, P.; Fox, C.H.; Ward, J.M.; Gonzalez, F.J. The T/EBP
null mouse: Thyroid-specific enhancer-binding protein is essential for the organogenesis of the thyroid, lung,
ventral forebrain, and pituitary. Genes Dev. 1996, 10, 60–69. [CrossRef] [PubMed]
34. Minoo, P.; Su, G.; Drum, H.; Bringas, P.; Kimura, S. Defects in tracheoesophageal and lung morphogenesis in
Nkx2.1p´{´q mouse embryos. Dev. Biol. 1999, 209, 60–71. [CrossRef] [PubMed]
35. Bohinski, R.J.; DiLauro, R.; Whitsett, J.A. The lung-specific surfactant protein B gene promoter is a target for
thyroid transcription factor 1 and hepatocyte nuclear factor 3, indicating common factors for organ-specific
gene expression along the foregut axis. Mol. Cell. Biol. 1994, 14, 5671–5681. [CrossRef] [PubMed]
36. Bruno, M.D.; Bohinski, R.J.; Huelsman, K.M.; Whitsett, J.A.; Korfhagen, T.R. Lung cell specific expression of
the murine surfactant protein A (SP-A) gene is mediated by interactions between the SPA promoter and
thyroid transcription factor-1. J. Biol. Chem. 1995, 270, 6531–6536. [PubMed]
37. Yan, C.; Sever, Z.; Whitsett, J.A. Upstream enhancer activity in the surfactant protein B gene is mediated by
thyroid transcription factor 1. J. Biol. Chem. 1995, 270, 24852–24857. [CrossRef] [PubMed]
38. Kelly, S.E.; Bachurski, C.J.; Burhans, M.S.; Glasser, S.W. Transcription of the lung-specific surfactant protein
C gene is mediated by thyroid transcription factor 1. J. Biol. Chem. 1996, 271, 6881–6888. [PubMed]
39. Zhang, L.; Whitsett, J.A.; Stripp, B.R. Regulation of Clara cell secretory protein gene transcription by thyroid
transcription factor-1. Biochim. Biophys. Acta 1997, 1350, 359–367. [CrossRef]
40. Lazzaro, D.; Price, M.; DeFelice, M.; DiLauro, R. The transcription factor TTF-1 is expressed at the onset
of thyroid and lung morphogenesis and in restricted regions of the foetal brain. Development 1991, 113,
1093–1104. [PubMed]
41. Ikeda, K.; Clark, J.C.; Shaw-White, J.R.; Stahlman, M.T.; Boutell, C.J.; Whitsett, J.A. Gene structure and
expression of human thyroid transcription factor-1 in respiratory epithelial cells. J. Biol. Chem. 1995, 270,
8108–8114. [CrossRef] [PubMed]
42. Kimura, S.; Ward, J.M.; Minoo, P. Thyroid-specific enhancerbinding protein/thyroid transcription factor 1
is not required for the initial specification of the thyroid and lung primordia. Biochimie 1999, 81, 321–327.
[CrossRef]
43. Lai, E.; Clark, K.L.; Burley, S.K.; Darnell, J.E., Jr. Hepatocyte nuclear factor 3/forkhead or “winged helix”
proteins: A family of transcription factors of diverse biologic function. Proc. Natl. Acad. Sci. USA 1993, 90,
10421–10423. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2016, 17, 128 17 of 27
44. Ikeda, K.; Shaw-White, J.R.; Wert, S.E.; Whitsett, J.A. Hepatocyte nuclear factor 3 activates transcription of
thyroid transcription factor 1 in respiratory epithelial cells. Mol. Cell. Biol. 1996, 16, 3626–3636. [CrossRef]
[PubMed]
45. Shaw-White, J.R.; Bruno, M.D.; Whitsett, J.A. GATA-6 activates transcription of thyroid transcription factor-1.
J. Biol. Chem. 1999, 274, 2658–2664. [CrossRef] [PubMed]
46. Monaghan, A.P.; Kaestner, K.H.; Grau, E.; Schutz, G. Postimplantation expression patterns indicate a role for
the mouse forkhead/HNF-3 α, β and γ genes in determination of the definitive endoderm, chordamesoderm
and neuroectoderm. Development 1993, 119, 563–578.
47. Ang, S.-L.; Wierda, A.; Wong, D.; Stevens, K.A.; Cascio, S.; Rossant, J.; Zaret, K.S. The formation and
maintenance of the definitive endoderm lineage in the mouse: Involvement of HNF-3/forkhead proteins.
Development 1993, 119, 1301–1315. [PubMed]
48. Kuo, C.T.; Morrisey, E.E.; Anandappa, R.; Sigrist, K.; Lu, M.M.; Parmacek, M.S.; Soudais, C.; Leiden, J.M.
GATA4 transcription factor is required for ventral morphogenesis and heart tube formation. Genes Dev. 1997,
11, 1048–1060. [CrossRef] [PubMed]
49. Alcorn, J.L.; Gao, E.; Chen, Q.; Smith, M.E.; Gerard, R.D.; Mendelson, C.R. Genomic elements involved in
transcriptional regulation of the surfactant protein-A gene. Mol. Endocrinol. 1993, 7, 1072–1085. [PubMed]
50. Bingle, C.D.; Hackett, B.P.; Moxley, M.; Longmore, W.; Gitlin, J.D. Role of HNF-3 α and HNF-3 β in Clara
cell secretory protein gene expression in bronchiolar epithelium. Biochem. J. 1995, 308, 197–202. [CrossRef]
[PubMed]
51. Ang, S.-L.; Rossant, J. HNF-3B is essential for node and notochord formation in mouse development. Cell
1994, 78, 561–74. [CrossRef]
52. Bogue, C.W.; Lou, L.J.; Vasavada, H.; Wilson, C.M.; Jacobs, H.C. Expression of Hoxb genes in the developing
mouse foregut and lung. Am. J. Respir. Cell Mol. Biol. 1996, 15, 163–171. [CrossRef] [PubMed]
53. Kappen, C. Hox genes in the lung. Am. J. Respir. Cell Mol. Biol. 1996, 15, 156–162. [CrossRef] [PubMed]
54. Volpe, M.V.; Martin, A.; Vosatka, R.J.; Mazzoni, C.L.; Nielsen, H.C. Hoxb-5 expression in the developing
mouse lung suggests a role in branching morphogenesis and epithelial cell fate. Histochem. Cell Biol. 1997,
108, 495–504. [CrossRef] [PubMed]
55. Bogue, C.W.; Gross, I.; Vasavada, H.; Dynia, D.W.; Wilson, C.M.; Jacobs, H.C. Identification of Hox genes in
newborn lung and effects of gestational age and retinoic acid on their expression. Am. J. Physiol. 1994, 266,
L448–L454. [PubMed]
56. Chinoy, M.R.; Volpe, M.V.; Cilley, R.E.; Zgleszewski, S.E.; Vosatka, R.J.; Martin, A.; Nielsen, H.C.;
Krummel, T.M. Growth factors and dexamethasone regulate Hoxb5 protein in cultured murine fetal lungs.
Am. J. Physiol. 1998, 274, L610–L620. [PubMed]
57. Cardoso, W.V.; Williams, M.C.; Mitsialis, S.A.; Joyce-Brady, M.; Rishi, A.K.; Brody, J.S. Retinoic acid induces
changes in the pattern of airway branching and alters epithelial cell differentiation in the developing lung
in vitro. Am. J. Respir. Cell Mol. Biol. 1995, 12, 464–476. [CrossRef] [PubMed]
58. Bellusci, S.; Henderson, R.; Winnier, G.; Oikawa, T.; Hogan, B.L. Evidence from normal expression and
targeted misexpression that bone morphogenetic protein-4 (BMP-4) plays a role in mouse embryonic lung
morphogenesis. Development 1996, 122, 1693–1702. [PubMed]
59. Weaver, M.; Yingling, Y.M.; Dunn, N.R.; Bellusci, S.; Hogan, B.L. BMP signaling regulates proximal-distal
differentiation of endoderm in mouse lung development. Development 1999, 126, 4005–4015. [PubMed]
60. Metzger, R.J.; Klein, O.D.; Martin, G.R.; Krasnow, M.A. The branching programme of mouse lung
development. Nature 2008, 453, 745–750. [CrossRef] [PubMed]
61. Tompkins, D.H.; Besnard, V.; Lange, A.W.; Keiser, A.R.; Wert, S.E.; Bruno, M.D.; Whitsett, J.A. Sox2 activates
cell proliferation and differentiation in the respiratory epithelium. Am. J. Respir. Cell Mol. Biol. 2011, 45,
101–110. [CrossRef] [PubMed]
62. Tompkins, D.H.; Besnard, V.; Lange, A.W.; Wert, S.E.; Keiser, A.R.; Smith, A.N.; Lang, R.; Whitsett, J.A. Sox2
is required for maintenance and differentiation of bronchiolar Clara, ciliated, and goblet cells. PLoS ONE
2009, 4, e8248. [CrossRef] [PubMed]
63. Que, J.; Luo, X.; Schwartz, R.J.; Hogan, B.L. Multiple roles for Sox2 in the developing and adult mouse
trachea. Development 2009, 136, 1899–1907. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2016, 17, 128 18 of 27
64. Que, J.; Okubo, T.; Goldenring, J.R.; Nam, K.T.; Kurotan, I.R.; Morrisey, E.E.; Taranova, O.; Pevny, L.H.;
Hogan, B.L. Multiple dose-dependent roles for Sox2 in the patterning and differentiation of anterior foregut
endoderm. Development 2007, 134, 2521–2531. [CrossRef] [PubMed]
65. Rockich, B.E.; Hrycaj, S.M.; Shih, H.P.; Nagy, M.S.; Ferguson, M.A.; Kopp, J.L.; Sander, M.; Wellik, D.M.;
Spence, J.R. Sox9 plays multiple roles in the lung epithelium during branching morphogenesis. Proc. Natl.
Acad. Sci. USA 2013, 110, E4456–E4464. [CrossRef] [PubMed]
66. Chen, F.; Cao, Y.; Qian, J.; Shao, F.; Niederreither, K.; Cardoso, W.V. A retinoic acid-dependent network in the
foregut controls formation of the mouse lung primordium. J. Clin. Investig. 2010, 120, 2040–2048. [CrossRef]
[PubMed]
67. De Langhe, S.P.; Carraro, G.; Tefft, D.; Li, C.; Xu, X.; Chai, Y.; Minoo, P.; Hajihosseini, M.K.; Drouin, J.;
Kaartinen, V.; et al. Formation and differentiation of multiple mesenchymal lineages during lung
development is regulated by β-catenin signaling. PLoS ONE 2008, 3, e1516. [CrossRef] [PubMed]
68. Goss, A.M.; Tian, Y.; Cheng, L.; Yang, J.; Zhou, D.; Cohen, E.D.; Morrisey, E.E. Wnt2 signaling is necessary
and sufficient to activate the airway smooth muscle program in the lung by regulating myocardin/Mrtf-B
and Fgf10 expression. Dev. Biol. 2011, 356, 541–552. [CrossRef] [PubMed]
69. Nyeng, P.; Norgaard, G.A.; Kobberup, S.; Jensen, J. FGF10 maintains distal lung bud epithelium and excessive
signaling leads to progenitor state arrest, distalization, and goblet cell metaplasia. BMC Dev. Biol. 2008, 8.
[CrossRef] [PubMed]
70. Ramasamy, S.K.; Mailleux, A.A.; Gupte, V.V.; Mata, F.; Sala, F.G.; Veltmaat, J.M.; del Moral, P.M.; de Langhe, S.;
Parsa, S.; Kelly, L.K.; et al. Fgf10 dosage is critical for the amplification of epithelial cell progenitors and for
the formation of multiple mesenchymal lineages during lung development. Dev. Biol. 2007, 307, 237–247.
[CrossRef] [PubMed]
71. Rawlins, E.L.; Clark, C.P.; Xue, Y.; Hogan, B.L. The Id2+ distal tip lung epithelium contains individual
multipotent embryonic progenitor cells. Development 2009, 136, 3741–3745. [CrossRef] [PubMed]
72. Volckaert, T.; Campbell, A.; Dill, E.; Li, C.; Minoo, P.; de Langhe, S. Localized Fgf10 expression is not required
for lung branching morphogenesis but prevents differentiation of epithelial progenitors. Development 2013,
140, 3731–3742. [CrossRef] [PubMed]
73. Izvolsky, K.I.; Shoykhet, D.; Yang, Y.; Yu, Q.; Nugent, M.A.; Cardoso, W.V. Heparan sulfate-FGF10 interactions
during lung morphogenesis. Dev. Biol. 2003, 258, 185–200. [CrossRef]
74. Izvolsky, K.I.; Zhong, L.; Wei, L.; Yu, Q.; Nugent, M.A.; Cardoso, W.V. Heparan sulfates expressed in the
distal lung are required for Fgf10 binding to the epithelium and for airway branching. Am. J. Physiol. Lung
Cell. Mol. Physiol. 2003, 285, L838–L846. [CrossRef] [PubMed]
75. Sedita, J.; Izvolsky, K.; Cardoso, W.V. Differential expression of heparan sulfate 6-O-sulfotransferase isoforms
in the mouse embryo suggests distinctive roles during organogenesis. Dev. Dyn. 2004, 231, 782–794.
[CrossRef] [PubMed]
76. McKeehan, W.L.; Wang, F.; Kan, M. The heparan sulfate-fibroblast growth factor family: Diversity of structure
and function. Prog. Nucleic Acid Res. Mol. Biol. 1998, 59, 135–176. [PubMed]
77. Chang, D.R.; Alanis, D.M.; Miller, R.K.; Ji, H.; Akiyama, H.; McCrea, P.D.; Chen, J. Lung epithelial branching
program antagonizes alveolar differentiation. Proc. Natl. Acad. Sci. USA 2013, 110, 18042–18051. [CrossRef]
[PubMed]
78. Volckaert, T.; de Langhe, S. Lung epithelial stem cells and their niches: Fgf10 takes center stage.
Fibrogenesis Tissue Repair. 2014, 8. [CrossRef] [PubMed]
79. Wang, Y.; Tian, Y.; Morley, M.P.; Lu, M.M.; Demayo, F.J.; Olson, E.N.; Morrisey, E.E. Development and
regeneration of Sox2+ endoderm progenitors are regulated by a Hdac1/2-Bmp4/Rb1 regulatory pathway.
Dev. Cell 2013, 24, 345–358. [CrossRef] [PubMed]
80. Shiratori, M.; Oshika, E.; Ung, L.P.; Singh, G.; Shinozuka, H.; Warburton, D.; Michalopoulos, G.; Katyal, S.L.
Keratinocyte growth factor and lung morphogenesis. Am. J. Respir. Cell Mol. Biol. 1996, 15, 328–338.
[CrossRef] [PubMed]
81. Cardoso, W.V.; Itoh, A.; Nogawa, H.; Mason, I.; Brody, J.S. FGF-1 and FGF-7 induce distinct patterns of
growth and differentiation in embryonic lung epithelium. Dev. Dyn. 1997, 8, 398–405. [CrossRef]
82. Shannon, J.M.; Gebb, S.A.; Nielson, L.D. Induction of alveolar type II cell differentiation in embryonic
tracheal epithelium in mesenchyme-free culture. Development 1999, 126, 1675–1688. [PubMed]
Int. J. Mol. Sci. 2016, 17, 128 19 of 27
83. Weinstein, M.; Xu, X.; Ohyama, K.; Deng, C.-X. FGFR-3 and FGFR-4 function cooperatively to direct
alveogenesis in the murine lung. Development 1998, 125, 3615–3623. [PubMed]
84. Plopper, C.G.; st George, J.A.; Read, L.C.; Nishio, S.J.; Weir, A.J.; Edwards, L.; Tarantal, A.F.; Pinkerton, K.E.;
Merritt, T.A.; Whitsett, J.A.; et al. Acceleration of type II cell differentiation in fetal rhesus monkey lung by
administration of EGF. Am. J. Physiol. 1992, 262, L313–L321. [PubMed]
85. Kolios, G.; Moodley, Y. Introduction to stem cells and regenerative medicine. Respiration 2013, 85, 3–10.
[CrossRef] [PubMed]
86. Potten, C.; Loeffler, M. Stem cells: Attributes, cycles, spirals, pitfalls and uncertainties. Lessons for and from
the crypt. Development 1990, 110, 1001–1020. [PubMed]
87. Leeman, K.T.; Fillmore, C.M.; Kim, C.F. Lung stem and progenitor cells in tissue homeostasis and disease.
Curr. Top. Dev. Biol. 2014, 107, 207–233. [PubMed]
88. Adamson, I.Y.; Bowden, D.H. The type 2 cell as progenitor of alveolar epithelial regeneration. A cytodynamic
study in mice after exposure to oxygen. Lab. Investig. 1974, 30, 35–42. [PubMed]
89. Adamson, I.Y.; Bowden, D.H. Origin of ciliated alveolar epithelial cells in bleomycin-induced lung injury.
Am. J. Pathol. 1977, 87, 569–580. [PubMed]
90. Adamson, I.Y.; Bowden, D.H. Bleomycin-induced injury and metaplasia of alveolar type 2 cells. Relationship
of cellular responses to drug presence in the lung. Am. J. Pathol. 1979, 96, 531–544. [PubMed]
91. Bowden, D.H.; Adamson, I.Y.; Wyatt, J.P. Reaction of the lung cells to a high concentration of oxygen.
Arch. Pathol. 1968, 86, 671–675. [PubMed]
92. Evans, M.J.; Cabral, L.C.; Stephens, R.J.; Freeman, G. Acute kinetic response and renewal of the alveolar
epithelium following injury by nitrogen dioxide. Chest 1974, 65, 62S–65S. [CrossRef] [PubMed]
93. Evans, M.J.; Cabral, L.J.; Stephens, R.J.; Freeman, G. Renewal of alveolar epithelium in the rat following
exposure to NO2. Am. J. Pathol. 1973, 70, 175–198. [PubMed]
94. Evans, M.J.; Cabral, L.J.; Stephens, R.J.; Freeman, G. Transformation of alveolar type 2 cells to type 1 cells
following exposure to NO2. Exp. Mol. Pathol. 1975, 22, 142–150. [CrossRef]
95. Evans, M.J.; Dekker, N.P.; Cabral-Anderson, L.J.; Freeman, G. Quantitation of damage to the alveolar
epithelium by means of type 2 cell proliferation. Am. Rev. Respir. Dis. 1978, 118, 787–790. [CrossRef]
[PubMed]
96. Rawlins, E.L.; Hogan, B.L. Epithelial stem cells of the lung: Privileged few or opportunities for many?
Development 2006, 133, 2455–2465. [CrossRef] [PubMed]
97. Rawlins, E.L.; Ostrowski, L.E.; Randell, S.H.; Hogan, B.L. Lung development and repair: Contribution of the
ciliated lineage. Proc. Natl. Acad. Sci. USA 2007, 104, 410–417. [CrossRef] [PubMed]
98. Rawlins, E.L.; Hogan, B.L. Ciliated epithelial cell lifespan in the mouse trachea and lung. Am. J. Physiol.
Lung Cell. Mol. Physiol. 2008, 295, L231–L234. [CrossRef] [PubMed]
99. Rawlins, E.L.; Okubo, T.; Que, J.; Xue, Y.; Clark, C.; Luo, X.; Hogan, B.L. Epithelial stem/progenitor cells
in lung postnatal growth, maintenance, and repair. Cold Spring Harb. Symp. Quant. Biol. 2008, 73, 291–295.
[CrossRef] [PubMed]
100. Borthwick, D.W.; Shahbazian, M.; Krantz, Q.T.; Dorin, J.R.; Randell, S.H. Evidence for stem-cell niches in the
tracheal epithelium. Am. J. Respir. Cell Mol. Biol. 2001, 24, 662–670. [CrossRef] [PubMed]
101. Rock, J.; Randell, S.; Hogan, B. Airway basal stem cells: A perspective on their roles in epithelial homeostasis
and remodeling. Dis. Models Mech. 2010, 3, 545–556. [CrossRef] [PubMed]
102. Rock, J.R.; Onaitis, M.W.; Rawlins, E.L.; Lu, Y.; Clark, C.P.; Xue, Y.; Randell, S.H.; Hogan, B.L. Basal cells
as stem cells of the mouse trachea and human airway epithelium. Proc. Natl. Acad. Sci. USA 2009, 106,
12771–12775. [CrossRef] [PubMed]
103. Cole, B.B.; Smith, R.W.; Jenkins, K.M.; Graham, B.B.; Reynolds, P.R.; Reynolds, S.D. Tracheal basal cells:
A facultative progenitor cell pool. Am. J. Pathol. 2010, 177, 362–376. [CrossRef] [PubMed]
104. Hong, K.U.; Reynolds, S.D.; Watkins, S.; Fuchs, E.; Stripp, B.R. In vivo differentiation potential of tracheal
basal cells: Evidence for multipotent and unipotent subpopulations. Am. J. Physiol. Lung Cell. Mol. Physiol.
2004, 286, L643–L649. [CrossRef] [PubMed]
105. Kumar, P.A.; Hu, Y.; Yamamoto, Y.; Hoe, N.B.; Wei, T.S.; Mu, D.; Hoe, N.B.; Wei, T.S.; Mu, D.; Sun, Y.; et al.
Distal airway stem cells yield alveoli in vitro and during lung regeneration following H1N1 influenza
infection. Cell 2011, 147, 525–538. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2016, 17, 128 20 of 27
106. Pardo-Saganta, A.; Law, B.M.; Gonzalez-Celeiro, M.; Vinarsky, V.; Rajagopal, J. Ciliated cells of
pseudostratified airway epithelium do not become mucous cells after ovalbumin challenge. Am. J. Respir.
Cell Mol. Biol. 2013, 48, 364–373. [CrossRef] [PubMed]
107. Rock, J.R.; Gao, X.; Xue, Y.; Randell, S.H.; Kong, Y.Y.; Hogan, B.L. Notch-dependent differentiation of adult
airway basal stem cells. Cell Stem Cell 2011, 8, 639–648. [CrossRef] [PubMed]
108. Reynolds, S.D.; Reynolds, P.R.; Pryhuber, G.S.; Finder, J.D.; Stripp, B.R. Secretoglobins SCGB3A1 and
SCGB3A2 define secretory cell subsets in mouse and human airways. Am. J. Respir. Crit. Care Med. 2002, 166,
1498–1509. [CrossRef] [PubMed]
109. Song, H.; Yao, E.; Lin, C.; Gacayan, R.; Chen, M.-H.; Chuang, P.-T. Functional characterization of pulmonary
neuroendocrine cells in lung development, injury, and tumorigenesis. Proc. Natl. Acad. Sci. USA 2012, 109,
17531–17536. [CrossRef] [PubMed]
110. Giangreco, A.; Reynolds, S.D.; Stripp, B.R. Terminal bronchioles harbor a unique airway stem cell population
that localizes to the bronchoalveolar duct junction. Am. J. Pathol. 2002, 161, 173–182. [CrossRef]
111. Rawlins, E.L.; Okubo, T.; Xue, Y.; Brass, D.M.; Auten, R.L.; Hasegawa, H.; Wang, F.; Hogan, B.L. The role of
Scgb1a1+ Clara cells in the long-term maintenance and repair of lung airway, but not alveolar, epithelium.
Cell Stem Cell 2009, 4, 525–534. [CrossRef] [PubMed]
112. Hong, K.U.; Reynolds, S.D.; Giangreco, A.; Hurley, C.M.; Stripp, B.R. Clara cell secretory protein-expressing
cells of the airway neuroepithelial body microenvironment include a label-retaining subset and are critical for
epithelial renewal after progenitor cell depletion. Am. J. Respir. Cell Mol. Biol. 2001, 24, 671–681. [CrossRef]
[PubMed]
113. Guha, A.; Vasconcelos, M.; Cai, Y.; Yoneda, M.; Hinds, A.; Qian, J.; Li, G.; Dickel, L.; Johnson, J.E.;
Kimura, S.; et al. Neuroepithelial body microenvironment is a niche for a distinct subset of Clara-like
precursors in the developing airways. Proc. Natl. Acad. Sci. USA 2012, 109, 12592–12597. [CrossRef]
[PubMed]
114. Morimoto, M.; Nishinakamura, R.; Saga, Y.; Kopan, R. Different assemblies of Notch receptors coordinate
the distribution of the major bronchial Clara, ciliated and neuroendocrine cells. Development 2012, 139,
4365–4373. [CrossRef] [PubMed]
115. Volckaert, T.; Dill, E.; Campbell, A.; Tiozzo, C.; Majka, S.; Bellusci, S.; de Langhe, S.P. Parabronchial smooth
muscle constitutes an airway epithelial stem cell niche in the mouse lung after injury. J. Clin. Investig. 2011,
121, 4409–4419. [CrossRef] [PubMed]
116. Giangreco, A.; Arwert, E.N.; Rosewell, I.R.; Snyder, J.; Watt, F.M.; Stripp, B.R. Stem cells are dispensable for
lung homeostasis but restore airways after injury. Proc. Natl. Acad. Sci. USA 2009, 106, 9286–9291. [CrossRef]
[PubMed]
117. Bertalanffy, F.D.; Leblond, C.P. Structure of respiratory tissue. Lancet 1955, 266, 1365–1368. [CrossRef]
118. Mason, R.J.; Williams, M.C. Type II alveolar cell. Defender of the alveolus. Am. Rev. Respir. Dis. 1977, 115,
81–91. [PubMed]
119. Kauffman, S.L. Alterations in cell proliferation in mouse lung following urethane exposure. 3. Effects of
chronic exposure on type 2 alveolar epithelial cell. Am. J. Pathol. 1972, 68, 317–326. [PubMed]
120. Kauffman, S.L. Kinetics of alveolar epithelial hyperplasia in lungs of mice exposed to urethane. I. quantitative
analysis of cell populations. Lab. Investig. 1974, 30, 170–175. [PubMed]
121. Kalina, M.; Riklis, S.; Blau, H. Pulmonary epithelial cell proliferation in primary culture of alveolar type II
cells. Exp. Lung Res. 1993, 19, 153–175. [CrossRef] [PubMed]
122. Witschi, H. Proliferation of type II alveolar cells: A review of common responses in toxic lung injury.
Toxicology 1976, 5, 267–277. [CrossRef]
123. Bitterman, P.B.; Polunovsky, V.A.; Ingbar, D.H. Repair after acute lung injury. Chest 1994, 105, 118S–121S.
[CrossRef] [PubMed]
124. Barkauskas, C.E.; Cronce, M.J.; Rackley, C.R.; Bowie, E.J.; Keene, D.R.; Stripp, B.R.; Randell, S.H.; Noble, P.W.;
Hogan, B.L. Type 2 alveolar cells are stem cells in adult lung. J. Clin. Investig. 2013, 123, 3025–3036. [CrossRef]
[PubMed]
125. Desai, T.J.; Brownfield, D.G.; Krasnow, M.A. Alveolar progenitor and stem cells in lung development,
renewal and cancer. Nature 2014, 507, 190–194. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2016, 17, 128 21 of 27
126. Kim, C.F.; Jackson, E.L.; Woolfenden, A.E.; Lawrence, S.; Babar, I.; Vogel, S.; Crowley, D.; Bronson, R.T.;
Jacks, T. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 2005, 121, 823–835.
[CrossRef] [PubMed]
127. Rock, J.R.; Barkauskas, C.E.; Cronce, M.J.; Xue, Y.; Harris, J.R.; Liang, J.; Noble, P.W.; Hogan, B.L. Multiple
stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal
transition. Proc. Natl. Acad. Sci. USA 2011, 108, E1475–E1483. [CrossRef] [PubMed]
128. Zheng, D.; Limmon, G.V.; Yin, L.; Leung, N.H.; Yu, H.; Chow, V.T.; Chen, J. Regeneration of alveolar type I
and II cells from Scgb1a1-expressing cells following severe pulmonary damage induced by bleomycin and
influenza. PLoS ONE 2012, 7, e48451. [CrossRef] [PubMed]
129. Da Silva Meirelles, L.; Chagastelles, P.C.; Nardi, N.B. Mesenchymal stem cells reside in virtually all post-natal
organs and tissues. J. Cell Sci. 2006, 119, 2204–2213. [CrossRef] [PubMed]
130. McQualter, J.L.; Brouard, N.; Williams, B.N.; Baird, B.N.; Sims-Lucas, S.; Yuen, K.; Nilsson, S.K.; Simmons, P.J.;
Bertoncello, I. Endogenous fibroblastic progenitor cells in the adult mouse lung are highly enriched in the
SCA-1 positive cell fraction. Stem Cells 2009, 27, 623–633. [CrossRef] [PubMed]
131. Summer, R.; Fitzsimmons, K.; Dwyer, D.; Murphy, J.; Fine, A. Isolation of an adult mouse lung mesenchymal
progenitor cell population. Am. J. Respir. Cell Mol. Biol. 2007, 37, 152–159. [CrossRef] [PubMed]
132. Hegab, A.E.; Kubo, H.; Fujino, N.; Suzuki, T.; He, M.; Kato, H.; Yamaya, M. Isolation and characterization of
murine multipotent lung stem cells. Stem Cells Dev. 2010, 19, 523–536. [CrossRef] [PubMed]
133. Reynolds, S.D.; Shen, H.; Reynolds, P.R.; Betsuyaku, T.; Pilewski, J.M.; Gambelli, F.; di Giuseppe, M.;
Ortiz, L.A.; Stripp, B.R. Molecular and functional properties of lung SP cells. Am. J. Physiol. Lung Cell.
Mol. Physiol. 2007, 292, L972–L983. [CrossRef] [PubMed]
134. Martin, J.; Helm, K.; Ruegg, P.; Varella-Garcia, M.; Burnham, E.; Majka, S. Adult lung side population cells
have mesenchymal stem cell potential. Cytotherapy 2008, 10, 140–151. [CrossRef] [PubMed]
135. Jarvinen, L.; Badri, L.; Wettlaufer, S.; Ohtsuka, T.; Standiford, T.J.; Toews, G.B.; Pinsky, D.J.; Peters-Golden, M.;
Lama, V.N. Lung resident mesenchymal stem cells isolated from human lung allografts inhibit T cell
proliferation via a soluble mediator. J. Immunol. 2008, 181, 4389–4396. [CrossRef] [PubMed]
136. Lama, V.N.; Smith, L.; Badri, L.; Flint, A.; Andrei, A.C.; Murray, S.; Wang, Z.; Liao, H.; Toews, G.B.;
Krebsbach, P.H.; et al. Evidence for tissueresident mesenchymal stem cells in human adult lung from studies
of transplanted allografts. J. Clin. Investig. 2007, 117, 989–996. [CrossRef] [PubMed]
137. Hennrick, K.T.; Keeton, A.G.; Nanua, S.; Kijek, T.G.; Goldsmith, A.M.; Sajjan, U.S.; Bentley, J.K.; Lama, V.N.;
Moore, B.B.; Schumacher, R.E.; et al. Lung cells from neonates show a mesenchymal stem cell phenotype.
Am. J. Respir. Crit. Care Med. 2007, 175, 1158–1164. [CrossRef] [PubMed]
138. Ingenito, E.P.; Sen, E.; Tsai, L.W. Design and testing of biological scaffolds for delivering reparative cells to
target sites in the lung. J. Tissue Eng. Regen. Med. 2010, 4, 259–272. [CrossRef] [PubMed]
139. Ingenito, E.P.; Tsai, L.; Murthy, S. Autologous lung-derived mesenchymal stem cell transplantation in
experimental emphysema. Cell Transplant. 2011, 21, 175–189. [CrossRef] [PubMed]
140. Dominici, M.; le Blanc, K.; Mueller, I.; Slaper-Cortenbach, I.; Marini, F.; Krause, D.; Deans, R.;
Keating, A.; Prockop, D.; Horwitz, E. Minimal criteria for defining multipotent mesenchymal stromal
cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8, 315–317.
[CrossRef] [PubMed]
141. Karoubi, G.; Cortes-Dericks, L.; Breyer, I.; Schmid, R.; Dutly, A. Identification of mesenchymal stromal cells
in human lung parenchyma capable of differentiating into aquaporin 5-expressing cells. Lab. Investig. 2009,
89, 1100–1114. [CrossRef] [PubMed]
142. Hegab, A.; Ha, V.; Gilbert, J.; Zhang, K.X.; Malkoski, S.P.; Chon, A.T.; Darmawan, D.O.; Bisht, B.; Ooi, A.T.;
Pellegrini, M.; et al. Novel stem/progenitor cell population from murine tracheal submucosal gland ducts
with multipotent regenerative potential. Stem Cells 2011, 29, 1283–1293. [CrossRef] [PubMed]
143. Morrisey, E.; Hogan, B. Preparing for the first breath: Genetic and cellular mechanisms in lung development.
Dev. Cell 2010, 18, 8–23. [CrossRef] [PubMed]
144. McQualter, J.; Yuen, K.; Williams, B.; Bertoncello, I. Evidence of an epithelial stem/progenitor cell hierarchy
in the adult mouse lung. Proc. Natl. Acad. Sci. USA 2010, 107, 1414–1419. [CrossRef] [PubMed]
145. Hoffman, A.; Paxson, J.; Mazan, M.; Davis, A.M.; Tyagi, S.; Murthy, S.; Ingenito, E.P. Lung-derived
mesenchymal stromal cell post-transplantation survival, persistence, paracrine expression, and repair
of elastase injured lung. Stem Cells Dev. 2011, 20, 1779–1792. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2016, 17, 128 22 of 27
146. Hogan, B.L.; Barkauskas, C.E.; Chapman, H.A.; Epstein, J.A.; Jain, R.; Hsia, C.C.; Niklason, L.; Calle, E.;
Le, A.; Randell, S.H.; et al. Repair and regeneration of the respiratory system: Complexity, plasticity, and
mechanisms of lung stem cell function. Cell Stem Cell 2014, 15, 123–138. [CrossRef] [PubMed]
147. Dane, D.M.; Yilmaz, C.; Estrera, A.S.; Hsia, C.C. Separating in vivo mechanical stimuli for
postpneumonectomy compensation: Physiological assessment. J. Appl. Physiol. 2013, 114, 99–106. [CrossRef]
[PubMed]
148. Ravikumar, P.; Yilmaz, C.; Bellotto, D.J.; Dane, D.M.; Estrera, A.S.; Hsia, C.C. Separating in vivo mechanical
stimuli for postpneumonectomy compensation: Imaging and ultrastructural assessment. J. Appl. Physiol.
2013, 114, 961–970. [CrossRef] [PubMed]
149. Ravikumar, P.; Yilmaz, C.; Dane, D.M.; Bellotto, D.J.; Estrera, A.S.; Hsia, C.C. Defining a stimuli-response
relationship in compensatory lung growth following major resection. J. Appl. Physiol. 2014, 116, 816–824.
[CrossRef] [PubMed]
150. Chen, L.; Acciani, T.; le Cras, T.; Lutzko, C.; Perl, A.K. Dynamic regulation of platelet-derived growth factor
receptor a expression in alveolar fibroblasts during realveolarization. Am. J. Respir. Cell Mol. Biol. 2012, 47,
517–527. [CrossRef] [PubMed]
151. Eisenhauer, P.; Earle, B.; Loi, R.; Sueblinvong, V.; Goodwin, M.; Allen, G.B.; Lundblad, L.; Mazan, M.R.;
Hoffman, A.M.; Weiss, D.J. Endogenous distal airway progenitor cells, lung mechanics, and disproportionate
lobar growth following long-term postpneumonectomy in mice. Stem Cells 2013, 31, 1330–1339. [CrossRef]
[PubMed]
152. Hoffman, A.M.; Shifren, A.; Mazan, M.R.; Gruntman, A.M.; Lascola, K.M.; Nolen-Walston, R.D.; Kim, C.F.;
Tsai, L.; Pierce, R.A.; Mecham, R.P.; et al. Matrix modulation of compensatory lung regrowth and progenitor
cell proliferation in mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 2010, 298, L158–L168. [CrossRef] [PubMed]
153. Hsia, C.C. Signals and mechanisms of compensatory lung growth. J. Appl. Physiol. 2004, 97, 1992–1998.
[CrossRef] [PubMed]
154. Thane, K.; Ingenito, E.P.; Hoffman, A.M. Lung regeneration and translational implications of the
postpneumonectomy model. Transl. Res. 2014, 163, 363–376. [CrossRef] [PubMed]
155. Voswinckel, R.; Motejl, V.; Fehrenbach, A.; Wegmann, M.; Mehling, T.; Fehrenbach, H.; Seeger, W.
Characterisation of post-pneumonectomy lung growth in adult mice. Eur. Respir. J. 2004, 24, 524–532.
[CrossRef] [PubMed]
156. Kaza, A.K.; Laubach, V.E.; Kern, J.A.; Long, S.M.; Fiser, S.M.; Tepper, J.A.; Nguyen, R.P.; Shockey, K.S.;
Tribble, C.G.; Kron, I.L. Epidermal growth factor augments postpneumonectomy lung growth. J. Thorac.
Cardiovasc. Surg. 2000, 120, 916–921. [CrossRef] [PubMed]
157. Kaza, A.K.; Kron, I.L.; Leuwerke, S.M.; Tribble, C.G.; Laubach, V.E. Keratinocyte growth factor enhances
post-pneumonectomy lung growth by alveolar proliferation. Circulation 2002, 106, I120–I124. [PubMed]
158. Al Alam, D.; Green, M.; Tabatabai Irani, R.; Parsa, S.; Danopoulos, S.; Sala, F.G.; Branch, J.; El Agha, E.;
Tiozzo, C.; Voswinckel, R.; et al. Contrasting expression of canonical Wnt signaling reporters TOPGAL,
BATGAL and Axin2(LacZ) during murine lung development and repair. PLoS ONE 2011, 6, e23139.
[CrossRef] [PubMed]
159. Aumiller, V.; Balsara, N.; Wilhelm, J.; Günther, A.; Königshoff, M. WNT/β-catenin signaling induces IL-1B
expression by alveolar epithelial cells in pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 2013, 49, 96–104.
[CrossRef] [PubMed]
160. Flozak, A.S.; Lam, A.P.; Russell, S.; Jain, M.; Peled, O.N.; Sheppard, K.A.; Beri, R.; Mutlu, G.M.; Budinger, G.R.;
Gottardi, C.J. β-Catenin/T-cell factor signaling is activated during lung injury and promotes the survival
and migration of alveolar epithelial cells. J. Biol. Chem. 2010, 285, 3157–3167. [CrossRef] [PubMed]
161. Hashimoto, S.; Chen, H.; Que, J.; Brockway, B.L.; Drake, J.A.; Snyder, J.C.; Randell, S.H.; Stripp, B.R.
β-Catenin-SOX2 signaling regulates the fate of developing airway epithelium. J. Cell Sci. 2012, 125, 932–942.
[CrossRef] [PubMed]
162. Zhang, Y.; Goss, A.M.; Cohen, E.D.; Kadzik, R.; Lepore, J.J.; Muthukumaraswamy, K.; Yang, J.; DeMayo, F.J.;
Whitsett, J.A.; Parmacek, M.S.; et al. A GATA6-Wnt pathway required for epithelial stem cell development
and airway regeneration. Nat. Genet. 2008, 40, 862–870. [CrossRef] [PubMed]
163. Zemke, A.C.; Teisanu, R.M.; Giangreco, A.; Drake, J.A.; Brockway, B.L.; Reynolds, S.D.; Stripp, B.R. β-Catenin
is not necessary for maintenance or repair of the bronchiolar epithelium. Am. J. Respir. Cell Mol. Biol. 2009,
41, 535–543. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2016, 17, 128 23 of 27
164. Tanjore, H.; Degryse, A.L.; Crossno, P.F.; Xu, X.C.; McConaha, M.E.; Jones, B.R.; Polosukhin, V.V.; Bryant, A.J.;
Cheng, D.S.; Newcomb, D.C.; et al. β-Catenin in the alveolar epithelium protects from lung fibrosis after
intratracheal bleomycin. Am. J. Respir. Crit. Care Med. 2013, 187, 630–639. [CrossRef] [PubMed]
165. Henderson, W.R., Jr.; Chi, E.Y.; Ye, X.; Tien, Y.T.; Zhou, B.; Borok, Z.; Knight, D.A.; Kahn, M. Inhibition
of Wnt/β-catenin/CREB binding protein (CBP) signaling reverses pulmonary fibrosis. Proc. Natl. Acad.
Sci. USA 2010, 107, 14309–14314. [CrossRef] [PubMed]
166. Chilosi, M.; Poletti, V.; Zamo, A.; Lestani, M.; Montagna, L.; Piccoli, P.; Pedron, S.; Bertaso, M.; Scarpa, A.;
Murer, B.; et al. Aberrant Wnt/β-catenin pathway activation in idiopathic pulmonary fibrosis. Am. J. Pathol.
2003, 162, 1495–1502. [CrossRef]
167. Morimoto, M.; Liu, Z.; Cheng, H.T.; Winters, N.; Bader, D.; Kopan, R. Canonical Notch signaling in the
developing lung is required for determination of arterial smooth muscle cells and selection of Clara vs.
ciliated cell fate. J. Cell Sci. 2010, 123, 213–224. [CrossRef] [PubMed]
168. Tsao, P.N.; Vasconcelos, M.; Izvolsky, K.I.; Qian, J.; Lu, J.; Cardoso, W.V. Notch signaling controls the balance
of ciliated and secretory cell fates in developing airways. Development 2009, 136, 2297–2307. [CrossRef]
[PubMed]
169. Xing, Y.; Li, A.; Borok, Z.; Li, C.; Minoo, P. NOTCH1 is required for regeneration of Clara cells during repair
of airway injury. Stem Cells 2012, 30, 946–955. [CrossRef] [PubMed]
170. Paul, M.K.; Bisht, B.; Darmawan, D.O.; Chiou, R.; Ha, V.L.; Wallace, W.D.; Chon, A.T.; Hegab, A.E.; Grogan, T.;
Elashoff, D.A.; et al. Dynamic changes in intracellular ROS levels regulate airway basal stem cell homeostasis
through Nrf2-dependent Notch signaling. Cell Stem Cell 2014, 15, 199–214. [CrossRef] [PubMed]
171. Yin, Z.; Gonzales, L.; Kolla, V.; Rath, N.; Zhang, Y.; Lu, M.M.; Kimura, S.; Ballard, P.L.; Beers, M.F.;
Epstein, J.A.; et al. Hop functions downstream of Nkx2.1 and GATA6 to mediate HDAC-dependent negative
regulation of pulmonary gene expression. Am. J. Physiol. Lung Cell. Mol. Physiol. 2006, 291, L191–L199.
[CrossRef] [PubMed]
172. Ito, K.; Ito, M.; Elliott, W.M.; Cosio, B.; Caramori, G.; Kon, O.M.; Barczyk, A.; Hayashi, S.; Adcock, I.M.;
Hogg, J.C.; et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N. Engl.
J. Med. 2005, 352, 1967–1976. [CrossRef] [PubMed]
173. Gunawardhana, L.P.; Gibson, P.G.; Simpson, J.L.; Powell, H.; Baines, K.J. Activity and expression of histone
acetylases and deacetylases in inflammatory phenotypes of asthma. Clin. Exp. Allergy 2014, 44, 47–57.
[CrossRef] [PubMed]
174. Tian, Y.; Zhang, Y.; Hurd, L.; Hannenhalli, S.; Liu, F.; Lu, M.M.; Morrisey, E.E. Regulation of lung endoderm
progenitor cell behavior by miR302/367. Development 2011, 138, 1235–1245. [CrossRef] [PubMed]
175. Ventura, A.; Young, A.G.; Winslow, M.M.; Lintault, L.; Meissner, A.; Erkeland, S.J.; Newman, J.; Bronson, R.T.;
Crowley, D.; Stone, J.R.; et al. Targeted deletion reveals essential and overlapping functions of the miR-17
through 92 family of miRNA clusters. Cell 2008, 132, 875–886. [CrossRef] [PubMed]
176. Lu, Y.; Thomson, J.M.; Wong, H.Y.; Hammond, S.M.; Hogan, B.L. Transgenic over-expression of the
microRNA miR-17–92 cluster promotes proliferation and inhibits differentiation of lung epithelial progenitor
cells. Dev. Biol. 2007, 310, 442–453. [CrossRef] [PubMed]
177. Herriges, M.J.; Swarr, D.T.; Morley, M.P.; Rathi, K.S.; Peng, T.; Stewart, K.M.; Morrisey, E.E. Long noncoding
RNAs are spatially correlated with transcription factors and regulate lung development. Genes Dev. 2014, 28,
1363–1379. [CrossRef] [PubMed]
178. Davidson, J.M. Biochemistry and turnover of lung interstitium. Eur. Respir. J. 1990, 3, 1048–1063. [PubMed]
179. Lane, S.; Rippon, H.J.; Bishop, A.E. Stem cells in lung repair and regeneration. Regen. Med. 2007, 2, 407–415.
[CrossRef] [PubMed]
180. Dunsmore, S.E.; Rannels, D.E. Extracellular matrix biology in the lung. Am. J. Physiol. 1996, 270, L3–L27.
[PubMed]
181. Suki, B.; Ito, S.; Stamenovic, D.; Lutchen, K.R.; Ingenito, E.P. Biomechanics of the lung parenchyma: Critical
roles of collagen and mechanical forces. J. Appl. Physiol. 2005, 98, 1892–1899. [CrossRef] [PubMed]
182. Kreis, T.; Vale, R. Guidebook to the Extracellular Matrix, Anchor, and Adhesion Proteins, 2nd ed.; Oxford University
Press: Oxford, UK, 1999; p. 422.
183. Olsen, C.O.; Isakson, B.E.; Seedorf, G.J.; Lubman, R.L.; Boitano, S. Extracellular matrix-driven alveolar
epithelial cell differentiation in vitro. Exp. Lung Res. 2005, 31, 461–482. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2016, 17, 128 24 of 27
184. Isakson, B.E.; Lubman, R.L.; Seedorf, G.J.; Boitano, S. Modulation of pulmonary alveolar type II cell
phenotype and communication by extracellular matrix and KGF. Am. J. Physiol. Cell Physiol. 2001, 281,
C1291–C1299. [PubMed]
185. Lin, Y.M.; Zhang, A.; Rippon, H.J.; Bismarck, A.; Bishop, A.E. Tissue engineering of lung: The effect of
extracellular matrix on the differentiation of embryonic stem cells to pneumocytes. Tissue Eng. Part A 2010,
16, 1515–1526. [CrossRef] [PubMed]
186. Petersena, T.H.; Calle, E.A.; Niklason, L.E. Strategies for lung regeneration. Mater. Today 2011, 14, 196–201.
[CrossRef]
187. Daley, W.P.; Peters, S.B.; Larsen, M. Extracellular matrix dynamics in development and regenerative medicine.
J. Cell Sci. 2008, 121, 255–264. [CrossRef] [PubMed]
188. Odorico, J.; Kaufman, D.; Thomson, J. Multilineage differentiation from human embryonic stem cell lines.
Stem Cells 2001, 19, 193–204. [CrossRef] [PubMed]
189. Takahashi, K.; Tanabe, K.; Ohnuki, M.; Narita, M.; Ichisaka, T.; Tomoda, K.; Yamanaka, S. Induction of
pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131, 861–872. [PubMed]
190. Takahashi, K.; Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast
cultures by defined factors. Cell 2006, 126, 663–676. [CrossRef] [PubMed]
191. Yu, J.; Vodyanik, M.; Smuga-Otto, K.; Antosiewicz-Bourget, J.; Frane, J.L.; Tian, S.; Nie, J.; Jonsdottir, G.A.;
Ruotti, V.; Stewart, R.; et al. Induced pluripotent stem cell lines derived from human somatic cells. Science
2007, 318, 1917–1920. [CrossRef] [PubMed]
192. Perl, A.; Kist, R.; Shan, Z.; Scherer, G.; Whitsett, J. Normal lung development and function after Sox9
inactivation in the respiratory epithelium. Genesis 2005, 41, 23–32. [CrossRef] [PubMed]
193. Shu, W.; Lu, M.; Zhang, Y.; Tucker, P.; Zhou, D.; Morrisey, E. Foxp2 and Foxp1 cooperatively regulate lung
and esophagus development. Development 2007, 134, 1991–2000. [CrossRef] [PubMed]
194. Van Haute, L.; de Block, G.; Liebaers, I.; Sermon, K.; DeRycke, M. Generation of lung epithelial-like tissue
from human embryonic stem cells. Respir. Res. 2009, 5. [CrossRef] [PubMed]
195. Green, M.; Chen, A.; Nostro, M.; d’Souza, S.; Lemischka, I.; Gouon-Evans, V.; Keller, G.; Snoeck, H.W.
Generation of anterior foregut endoderm from human embryonic and induced pluripotent stem cells.
Nat. Biotechnol. 2011, 29, 267–272. [CrossRef] [PubMed]
196. Mou, H.; Zhao, R.; Sherwood, R.; Ahfeldt, T.; Lapey, A.; Wain, J.; Sicilian, L.; Izvolsky, K.; Musunuru, K.;
Cowan, C.; et al. Generation of multipotent lung and airway progenitors from mouse ESCs and
patient-specific cystic fibrosis iPSCs. Cell Stem Cell 2012, 10, 385–397. [CrossRef] [PubMed]
197. Longmire, T.A.; Ikonomou, L.; Hawkins, F.; Christodoulou, C.; Cao, Y.; Jean, J.C.; Kwok, L.W.; Mou, H.;
Rajagopal, J.; Shen, S.S.; et al. Efficient derivation of purified lung and thyroid progenitors from embryonic
stem cells. Cell Stem Cell 2012, 10, 398–411. [CrossRef] [PubMed]
198. Wong, A.; Bear, C.; Chin, S.; Pasceri, P.; Thompson, T.O.; Huan, L.J.; Ratjen, F.; Ellis, J.; Rossant, J. Directed
differentiation of human pluripotent stem cells into mature airway epithelia expressing functional CFTR
protein. Nat. Biotechnol. 2012, 9, 876–882. [CrossRef] [PubMed]
199. Huang, S.X.; Islam, M.N.; O’Neill, J.; Hu, Z.; Yang, Y.G.; Chen, Y.W.; Mumau, M.; Green, M.D.;
Vunjak-Novakovic, G.; Bhattacharya, J.; et al. Efficient generation of lung and airway epithelial cells
from human pluripotent stem cells. Nat. Biotechnol. 2014, 32, 84–91. [CrossRef] [PubMed]
200. Berry, M.F.; Engler, A.J.; Woo, Y.J.; Pirolli, T.J.; Bish, L.T.; Jayasankar, V.; Morine, K.J.; Gardner, T.J.;
Discher, D.E.; Sweeney, H.L. Mesenchymal stem cell injection after myocardial infarction improves
myocardial compliance. Am. J. Physiol. Heart Circ. Physiol. 2006, 290, 196–203. [CrossRef] [PubMed]
201. Kotton, D.N.; Ma, B.Y.; Cardoso, W.V.; Sanderson, E.A.; Summer, R.S.; Williams, M.C.; Fine, A.
Bone marrow-derived cells as progenitors of lung alveolar epithelium. Development 2001, 128, 5181–5188.
[PubMed]
202. Morigi, M.; Imberti, B.; Zoja, C.; Corna, D.; Tomasoni, S.; Abbate, M.; Rottoli, D.; Angioletti, S.; Benigni, A.;
Perico, N.; et al. Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function
in acute renal failure. J. Am. Soc. Nephrol. 2004, 15, 1794–1804. [CrossRef] [PubMed]
203. Rojas, M.; Xu, J.; Woods, C.R.; Mora, A.L.; Spears, W.; Roman, J.; Brigham, K.L. Bone marrow-derived
mesenchymal stem cells in repair of the injured lung. Am. J. Respir. Cell Mol. Biol. 2005, 33, 145–152.
[CrossRef] [PubMed]
Int. J. Mol. Sci. 2016, 17, 128 25 of 27
204. Baber, S.R.; Deng, W.; Master, R.G.; Bunnell, B.A.; Taylor, B.K.; Murthy, S.N.; Hyman, A.L.; Kadowitz, P.J.
Intratracheal mesenchymal stem cell administration attenuates monocrotaline-induced pulmonary
hypertension and endothelial dysfunction. Am. J. Physiol. Heart Circ. Physiol. 2007, 292, 120–128.
205. Burdon, T.J.; Paul, A.; Noiseux, N.; Prakash, S.; Shum-Tim, D. Bone marrow stem cell derived paracrine
factors for regenerative medicine: Current perspectives and therapeutic potential. Bone Marrow Res. 2011,
2011, 207326. [CrossRef] [PubMed]
206. Nemeth, K.; Leelahavanichkul, A.; Yuen, P.S.; Mayer, B.; Parmelee, A.; Doi, K.; Robey, P.G.;
Leelahavanichkul, K.; Koller, B.H.; Brown, J.M.; et al. Bone marrow stromal cells attenuate sepsis
via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10
production. Nat. Med. 2009, 15, 42–49. [CrossRef] [PubMed]
207. Ortiz, L.A.; Dutreil, M.; Fattman, C.; Pandey, A.C.; Torres, G.; Go, K.; Phinney, D.G. Interleukin 1 receptor
antagonist mediates the anti-inflammatory and anti-fibrotic effect of mesenchymal stem cells during lung
injury. Proc. Natl. Acad. Sci. USA 2007, 104, 11002–11007. [CrossRef] [PubMed]
208. Zhen, G.; Liu, H.; Gu, N.; Zhang, H.; Xu, Y.; Zhang, Z. Mesenchymal stem cells transplantation protects
against rat pulmonary emphysema. Front. Biosci. 2008, 13, 3415–3422. [CrossRef] [PubMed]
209. Akram, K.M.; Samad, S.; Spiteri, M.A.; Forsyth, N.R. Mesenchymal stem cells promote alveolar epithelial cell
wound repair in vitro through distinct migratory and paracrine mechanisms. Respir. Res. 2013, 14. [CrossRef]
[PubMed]
210. Gnecchi, M.; Zhang, Z.; Ni, A.; Dzau, V.J. Paracrine mechanisms in adult stem cell signalling and therapy.
Circ. Res. 2008, 103, 1204–1219. [CrossRef] [PubMed]
211. Suzuki, G.; Iyer, V.; Lee, T.C.; Canty, J.M., Jr. Autologous mesenchymal stem cells mobilize cKit+ and CD133+
bone marrow progenitor cells and improve regional function in hibernating myocardium. Circ. Res. 2011,
109, 1044–1054. [CrossRef] [PubMed]
212. Islam, M.; Das, S.; Emin, M.; Wei, M.; Sun, L.; Westphalen, K.; Rowlands, D.J.; Quadri, S.K.; Bhattacharya, S.;
Bhattacharya, J. Mitochondrial transfer from bone marrow derived stromal cells to pulmonary alveoli
protects against acute lung injury. Nat. Med. 2012, 18, 759–765. [CrossRef] [PubMed]
213. Lee, C.; Mitsialis, S.; Aslam, M.; Vitali, S.; Vergadi, E.; Konstantinou, G.; Sdrimas, K.; Fernandez-Gonzalez, A.;
Kourembanas, S. Exosomes mediate the cytoprotective action of mesenchymal stromal cells on
hypoxia-induced pulmonary hypertension. Circulation 2012, 126, 2601–2611. [CrossRef] [PubMed]
214. Akram, K.M.; Samad, S.; Spiteri, M.; Forsyth, N.R. Mesenchymal stem cell therapy and lung diseases.
Adv. Biochem. Eng. Biotechnol. 2013, 130, 105–129. [PubMed]
215. Ware, L.B.; Matthay, M.A. The acute respiratory distress syndrome. N. Engl. J. Med. 2000, 342, 1334–1349.
[CrossRef] [PubMed]
216. Danchuk, S.; Joni, H.; Hossain, F.F.; Sorge, R.F.; Ramsey, A.; Ryan, W.; Sullivan, D.E. Human multipotent
stromal cells attenuate lipopolysaccharide-induced acute lung injury in mice via secretion of tumor necrosis
factor-α-induced protein 6. Stem Cell Res. Ther. 2010, 2, 27–42.
217. Gupta, N.; Su, X.; Popov, B.; Lee, J.W.; Serikov, V.; Matthay, M.A. Intrapulmonary delivery of bone
marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung
injury in mice. J. Immunol. 2007, 179, 855–1863. [CrossRef]
218. Lee, J.W.; Fang, X.; Gupta, N.; Serikov, V.; Matthay, M.A. Allogeneic human mesenchymal stem cells for
treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung. Proc. Natl. Acad.
Sci. USA 2009, 106, 16357–16362. [CrossRef] [PubMed]
219. Mei, S.H.J.; McCarter, S.D.; Deng, Y.; Parker, C.H.; Liles, W.C.; Stewart, D.J. Prevention of LPS-induced acute
lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1. PLoS Med. 2007, 4, e269.
[CrossRef] [PubMed]
220. Chang, Y.S.; Oh, W.; Choi, S.J.; Sung, D.K.; Kim, S.Y.; Choi, E.Y.; Kang, S.; Jin, H.J.; Yang, Y.S.; Park, W.S.
Human umbilical cord blood-derived mesenchymal stem cells attenuate hyperoxia-induced lung injury in
neonatal rats. Cell Transplant. 2009, 18, 869–886. [CrossRef] [PubMed]
221. Krasnodembskaya, A.; Song, Y.; Fang, X.; Gupta, N.; Serikov, V.; Lee, J.W.; Matthay, M.A. Antibacterial effect
of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37.
Stem Cells 2010, 28, 2229–2238. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2016, 17, 128 26 of 27
222. Wilson, J.G.; Liu, K.D.; Zhuo, H.; Caballero, L.; McMillan, M.; Fang, X.; Cosgrove, K.; Vojnik, R.; Calfee, C.S.;
Lee, J.W.; et al. Mesenchymal stem (stromal) cells for treatment of ARDS: A phase 1 clinical trial.
Lancet Respir. Med. 2015, 3, 24–32. [CrossRef]
223. Kanki-Horimoto, S.; Horimoto, H.; Mieno, S.; Kishida, K.; Watanabe, F.; Furuya, E.; Katsumata, T.
Implantation of mesenchymal stem cells overexpressing endothelial nitric oxide synthase improves right
ventricular impairments caused by pulmonary hypertension. Circulation 2006, 114, I181–I185. [CrossRef]
[PubMed]
224. Liang, O.; Mitsialis, S.; Chang, M.; Vergadi, E.; Lee, C.; Aslam, M.; Fernandez-Gonzalez, A.; Liu, X.; Baveja, R.;
Kourembanas, S. Mesenchymal stromal cells expressing heme oxygenase-1 reverse pulmonary hypertension.
Stem Cells 2011, 29, 99–107. [CrossRef] [PubMed]
225. Lomas, N.J.; Watts, K.L.; Akram, K.M.; Forsyth, N.R.; Spiteri, M.A. Idiopathic pulmonary fibrosis:
Immunohistochemical analysis provides fresh insights into lung tissue remodelling with implications
for novel prognostic markers. Int. J. Clin. Exp. Pathol. 2012, 5, 58–71. [PubMed]
226. Akram, K.M.; Lomas, N.J.; Spiteri, M.A.; Forsyth, N.R. Club cells inhibit alveolar epithelial wound repair via
TRAIL-dependent apoptosis. Eur. Respir. J. 2013, 41, 683–694. [CrossRef] [PubMed]
227. Akram, K.M.; Lomas, N.J.; Forsyth, N.R.; Spiteri, M.A. Alveolar epithelial cells in idiopathic pulmonary
fibrosis display upregulation of TRAIL, DR4 and DR5 expression with simultaneous preferential
over-expression of pro-apoptotic marker p53. Int. J. Clin. Exp. Pathol. 2014, 7, 552–564. [PubMed]
228. Aguilar, S.; Scotton, C.; McNutty, K.; Nye, E.; Stamp, G.; Laurent, G.; Bonnet, D.; Janes, S.M. Bone marrow
stem cells expressing keratinocyte growth factor via an inducible lentivirus protects against bleomycin
induced pulmonary fibrosis. PLoS ONE 2009, 4, e8013. [CrossRef] [PubMed]
229. Kumamoto, M.; Nishiwaki, T.; Matsuo, N.; Kimura, H.; Matsushima, K. Minimally cultured bone marrow
mesenchymal stem cells ameliorate fibrotic lung injury. Eur. Respir. J. 2009, 34, 740–748. [CrossRef] [PubMed]
230. Ortiz, L.; Gambelli, F.; McBride, C.; Gaupp, D.; Baddoo, M.; Kaminski, N.; Phinney, D.G. Mesenchymal stem
cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects.
Proc. Natl. Acad. Sci. USA 2003, 100, 8407–8411. [CrossRef] [PubMed]
231. Guo, J.; Yi, E.S.; Havill, A.M.; Sarosi, I.; Whitcomb, L.; Yin, S.; Middleton, S.C.; Piguet, P.; Ulich, T.R.
Intravenous keratinocyte growth factor protects against experimental pulmonary injury. Am. J. Physiol. 1998,
275, 800–805.
232. Panos, R.J.; Rubin, J.S.; Csaky, K.G.; Aaronson, S.A.; Mason, R.J. Keratinocyte growth factor and
hepatocyte growth factor/scatter factor are heparin-binding growth factors for alveolar type II cells in
fibroblast-conditioned medium. J. Clin. Investig. 1993, 92, 969–977. [CrossRef] [PubMed]
233. Yano, T.; Mason, R.J.; Pan, T.; Deterding, R.R.; Nielsen, L.D.; Shannon, J.M. KGF regulates pulmonary
epithelial proliferation and surfactant protein gene expression in adult rat lung. Am. J. Physiol. Lung Cell.
Mol. Physiol. 2000, 279, 1146–1158.
234. Chapman, H.A.; Allen, C.L.; Stone, O.L. Abnormalities in pathways of alveolar fibrin turnover among
patients with interstitial lung disease. Am. Rev. Respir. Dis. 1986, 133, 437–443. [PubMed]
235. Abreu, S.C.; Antunes, M.A.; Pelosi, P.; Morales, M.M.; Rocco, P.R. Mechanisms of cellular therapy in
respiratory diseases. Intensive Care Med. 2011, 37, 1421–1431. [CrossRef] [PubMed]
236. Yuhgetsu, H.; Ohno, Y.; Funaguchi, N.; Asai, T.; Sawada, M.; Takemura, G.; Minatoguchi, S.; Fujiwara, H.;
Fujiwara, T. Beneficial effects of autologous bone marrow mononuclear cell transplantation against
elastase-induced emphysema in rabbits. Exp. Lung Res. 2006, 32, 413–426. [CrossRef] [PubMed]
237. Weiss, D.; Casaburi, R.; Flannery, R.; Leroux-Williams, M.; Tashkin, D. A placebo-controlled, randomized
trial of mesenchymal stem cells in COPD. Chest 2013, 143, 1590–1598. [CrossRef] [PubMed]
238. Nichols, J.E.; Cortiella, J. Engineering of a complex organ: Progress toward development of
a tissue-engineered lung. Proc. Am. Thorac. Soc. 2008, 5, 723–730. [CrossRef] [PubMed]
239. Tomei, A.A.; Boschetti, F.; Gervaso, F.; Swartz, M.A. 3D collagen cultures under welldefined dynamic strain:
A novel strain device with a porous elastomeric support. Biotechnol. Bioeng. 2009, 103, 217–225. [CrossRef]
[PubMed]
240. Omori, K.; Tada, Y.; Suzuki, T.; Nomoto, Y.; Matsuzuka, T.; Kobayashi, K.; Nakamura, T.; Kanemaru, S.;
Yamashita, M.; Asato, R. Clinical application of in situ tissue engineering using a scaffolding technique
for reconstruction of the larynx and trachea. Ann. Otol. Rhinol. Laryngol. 2008, 117, 673–678. [CrossRef]
[PubMed]
Int. J. Mol. Sci. 2016, 17, 128 27 of 27
241. Omori, K.; Nakamura, T.; Kanemaru, S.; Magrufov, A.; Yamashita, M.; Shimizu, Y. In situ tissue engineering
of the cricoid and trachea in a canine model. Ann. Otol. Rhinol. Laryngol. 2008, 117, 609–613. [CrossRef]
[PubMed]
242. Macchiarini, P.; Jungebluth, P.; Go, T.; Asnaghi, M.A.; Rees, L.E.; Cogan, T.A.; Dodson, A.; Martorell, J.;
Bellini, S.; Parnigotto, P.P.; et al. Clinical transplantation of a tissue-engineered airway. Lancet 2008, 372,
2023–2030. [CrossRef]
243. Ott, H.C.; Clippinger, B.; Conrad, C.; Schuetz, C.; Pomerantseva, I.; Ikonomou, L.; Kotton, D.; Vacanti, J.P.
Regeneration and orthotopic transplantation of a bioartificial lung. Nat. Med. 2010, 16, 927–933. [CrossRef]
[PubMed]
244. Petersen, T.H.; Calle, E.A.; Zhao, L.; Lee, E.J.; Gui, L.; Raredon, M.B.; Gavrilov, K.; Yi, T.; Zhuang, Z.W.;
Breuer, C.; et al. Tissue-engineered lungs for in vivo implantation. Science 2010, 329, 538–541. [CrossRef]
[PubMed]
245. Price, A.P.; England, K.A.; Matson, A.M.; Blazar, B.R.; Panoskaltsis-Mortari, A. Development of
a decellularized lung bioreactor system for bioengineering the lung: The matrix reloaded. Tissue Eng.
Part A 2010, 16, 2581–2591. [CrossRef] [PubMed]
246. Daly, A.B.; Wallis, J.M.; Borg, Z.D.; Bonvillain, R.W.; Deng, B.; Ballif, B.A.; Jaworski, D.M.; Allen, G.B.;
Weiss, D.J. Initial binding and recellularization of decellularized mouse lung scaffolds with bone
marrow–derived mesenchymal stromal cells. Tissue Eng. Part A 2012, 18, 1–16. [CrossRef] [PubMed]
247. Wallis, J.M.; Borg, Z.D.; Daly, A.B.; Deng, B.; Ballif, B.A.; Allen, G.B.; Jaworski, D.M.; Weiss, D.J. Comparative
assessment of detergent-based protocols for mouse lung de-cellularization and re-cellularization. Tissue Eng.
Part C Methods 2012, 18, 420–432. [CrossRef] [PubMed]
248. Cortiella, J.; Niles, J.; Cantu, A.; Brettler, A.; Pham, A.; Vargas, G.; Winston, S.; Wang, J.; Walls, S.; Nichols, J.E.
Influence of acellular natural lung matrix on murine embryonic stem cell differentiation and tissue formation.
Tissue Eng. Part A 2010, 16, 2565–2580. [CrossRef] [PubMed]
249. Ghaedi, M.; Calle, E.A.; Mendez, J.J.; Gard, A.L.; Balestrini, J.; Booth, A.; Bove, P.F.; Gui, L.; White, E.S.;
Niklason, L.E. Human IPS cell-derived alveolar epithelium repopulates lung extracellular matrix.
J. Clin. Investig. 2013, 123, 4950–4962. [CrossRef] [PubMed]
250. Bonvillain, R.W.; Scarritt, M.E.; Pashos, N.C.; Mayeux, J.P.; Meshberger, C.L.; Betancourt, A.M.; Sullivan, D.E.;
Bunnell, B.A. Nonhuman primate lung decellularization and recellularization using a specialized large-organ
bioreactor. J. Vis. Exp. 2013, 82. [CrossRef] [PubMed]
251. Booth, A.J.; Hadley, R.; Cornett, A.M.; Dreffs, A.A.; Matthes, S.A.; Tsui, J.L.; Weiss, K.; Horowitz, J.C.;
Fiore, V.F.; Barker, T.H.; et al. Acellular normal and fibrotic human lung matrices as a culture system for
in vitro investigation. Am. J. Respir. Crit. Care Med. 2012, 186, 866–876. [CrossRef] [PubMed]
252. Gilpin, S.E.; Guyette, J.P.; Gonzalez, G.; Ren, X.; Asara, J.M.; Mathisen, D.J.; Vacanti, J.P.; Ott, H.C. Perfusion
decellularization of human and porcine lungs: Bringing the matrix to clinical scale. J. Heart Lung Transplant.
2013, 33, 298–308. [CrossRef] [PubMed]
253. Nichols, J.E.E.; Niles, J.; Riddle, M.; Vargas, G.; Schilagard, T.; Ma, L.; Edward, K.; La Francesca, S.;
Sakamoto, J.; Vega, S.; et al. Production and assessment of decellularized pig and human lung scaffolds.
Tissue Eng. Part A 2013, 19, 2045–2062. [CrossRef] [PubMed]
254. Wagner, D.E.; Bonenfant, N.R.; Sokocevic, D.; Desarno, M.J.; Borg, Z.D.; Parsons, C.S.; Brooks, E.M.; Platz, J.J.;
Khalpey, Z.I.; Hoganson, D.M.; et al. Three-dimensional scaffolds of acellular human and porcine lungs
for high throughput studies of lung disease and regeneration. Biomaterials 2014, 35, 2664–2679. [CrossRef]
[PubMed]
© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons by Attribution
(CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
